<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":8512,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/a4610bb61aea3199fe1b6cfffdb7f388'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/a4610bb61aea3199fe1b6cfffdb7f388'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1H4P1K003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1H4P1K003">Previous Result: <span>United States v. Baum, 461 Fed. Appx. 73...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1H4P22003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1H4P22003">Next Result: <span>United States v. Clay, 457 Fed. Appx. 88...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation negative" title="Negative"></div>
<div class='title left' title='Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion'>
Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1H4P3U003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs.</div>
<div class='displayCitation'>101 U.S.P.Q.2d 1641</div>
<div class='displayCitation'>2012 BL 32360</div>
<div class='displayCitation'>2012 BL 35737</div>
<div class='displayCitation'>2012 BL 92776</div>
<div class='displayCitation'>670 F.3d 1171</div>
<div class='displayCitation'>bna a0d0r6x6h0</div>
<div class='displayCitation'>bna a0d0u7h3t4</div>
<div class='displayCitation'>wkffecase:25768111</div>
<div class='displayCitation'>wkffecase:25768511</div>
<div class='displayCitation'>wkffecase:25937636</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1H4P3U003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1H4P3U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1H4P3U003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1H4P3U003" /><input id="title" name="title" type="hidden" value="Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 670 F.3d 1171, 101 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="NEGATIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="a4610bb61aea3199fe1b6cfffdb7f388" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1H4P3U003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fa%34%36%31%30bb%36%31aea%33%31%39%39fe%31b%36cfffdb%37f%33%38%38%2Fdocument%2FX%31H%34P%33U%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/bcite/X1H4P3U003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/bcite/X1H4P3U003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/bcite/X1H4P3U003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/related_content/X1H4P3U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1688765136899";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">670 F.3d 1171</div>
<div class="cite" data-cite-type="ReporterOfDecisions">101 U.S.P.Q.2d 1641</div>
<div class="cite" data-cite-type="DocketNumber">2010-1510</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 32360</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
BARD PERIPHERAL VASCULAR, INC. AND DAVID GOLDFARB, M.D.,
Plaintiffs/Counterclaim Defendants-Appellees, AND C.R. BARD, INC.,
Counterclaim Defendant-Appellee, v. W.L. GORE &amp; ASSOCIATES, INC.,
Defendant/Counterclaimant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2010-1510.
</center></p>
<p><center>
Decided: February 10, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442094" href="#headnote_ref_pq2-dec_442094">[1]</a> <span>Patentability/Validity &mdash; Date of invention &mdash;
Conception </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0403" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0403">&#9658;115.0403</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Inventorship </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.13" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.13">&#9658;115.13</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's finding that manufacturing plant manager, who provided expanded polytetrafluoroethylene (ePTFE) tubes to named inventor of patent in suit, was not joint inventor of that patent, which claims prosthetic vascular grafts made from ePTFE, since asserted claims require use of ePTFE having microscopic superstructure of nodes and interconnecting fibrils, with specified range of fibril lengths or &ldquo;internodal distances,&rdquo; since there is no evidence that plant manager knew fibril lengths of materials tested by inventor before his reduction to practice, or that plant manager either recognized or appreciated critical nature of internodal distance and communicated that key requirement to inventor before he reduced invention to practice, since potential use of ePTFE for grafts was not new concept, and any suggestion by plant manager to use that material was insignificant, and since jury thus could have reasonably concluded that plant manager's collaboration with inventor did not contribute to conception of invention in significant manner.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442095" href="#headnote_ref_pq2-dec_442095">[2]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Prior art </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0703">&#9658;115.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Specification &mdash; Enablement </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1105" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1105">&#9658;115.1105</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports finding that invention of patent directed to prosthetic vascular grafts made from expanded polytetrafluoroethylene
(ePTFE) is not enabled by prior art article that reported successful use of grafts made from ePTFE, since plaintiff's technical expert testified that reference did not provide sufficient information, including characteristics of graft material, for doctor to recreate working vascular graft, since defendant's fact witness testified that results reported in reference could not be replicated because article &ldquo;did not define anything,&rdquo; since plaintiff presented evidence that other experts in field were unable to reproduce grafts that would duplicate results reported in article, and since plaintiff therefore presented substantial evidence that article does not enable person of ordinary skill in art to make invention without undue experimentation, and thus cannot be used as anticipatory prior art.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442096" href="#headnote_ref_pq2-dec_442096">[3]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Identity of elements </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0704" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0704">&#9658;115.0704</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports finding that invention of patent directed to prosthetic vascular grafts made from expanded polytetrafluoroethylene
(ePTFE) was not anticipated by prior art article that reported successful use of grafts made from ePTFE, since asserted claims require use of ePTFE having microscopic superstructure of nodes and interconnecting fibrils, with specified range of fibril lengths or &ldquo;internodal distances,&rdquo; since defendant's technical expert testified that article does not refer to internodal distance, since evidence indicates that claimed internodal distances could not be determined from figure in article, and since article was before U.S. Patent and Trademark Office during prosecution of patent in suit, and PTO did not find that article anticipated claimed invention.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442097" href="#headnote_ref_pq2-dec_442097">[4]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Failure of others to remedy </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0910" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0910">&#9658;115.0910</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's finding that invention of patent directed to prosthetic vascular grafts made from expanded polytetrafluoroethylene
(ePTFE) would not have been obvious in light of two prior art references, whether considered separately or in combination, since jury heard evidence that both references were repeatedly considered by U.S. Patent and Trademark Office and were found not to invalidate claimed invention, since author of one reference stated in affidavit that prosthetic vascular structure conceived and developed in claimed invention was &ldquo;by no means obvious&rdquo; to researchers at relevant time, since inventor of patent in suit testified that neither reference, either alone or in combination, taught his invention, since evidence shows that other researchers were unable to solve problems with graft development addressed by claimed invention, even after both references were published, and since asserted claims require use of ePTFE having microscopic superstructure of nodes and interconnecting fibrils, with specified range of fibril lengths or &ldquo;internodal distances,&rdquo; and neither reference disclosed importance of internodal distance.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442098" href="#headnote_ref_pq2-dec_442098">[5]</a> <span>Patentability/Validity &mdash; Specification &mdash; Written description </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1103" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1103">&#9658;115.1103</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's conclusion that certain claims of patent for prosthetic vascular grafts made from expanded polytetrafluoroethylene
(ePTFE), which are not limited to prosthesis having wall thickness of 0.2 to 0.8 mm, are not invalid for lack of written description, since written description states that wall thickness is &ldquo;factor&rdquo;
affecting establishment and maintenance of viable neointima in grafts, and that grafts &ldquo;embodying the claimed invention, having wall thicknesses in the range between 0.2 to 0.8 millimeters &hellip; have exhibited excellent mechanical properties,&rdquo; whereas grafts &ldquo;falling outside these ranges have been found to be marginal or clinically unacceptable,&rdquo; but language of patent does not mandate wall thickness within stated range for claimed invention, since, in interference involving patent, U.S. Patent and Trademark Office proposed count that did not include wall thickness limitation, and denied motion to amend count to include wall thickness range, and since inventor testified at trial that his invention did not require specific wall thickness.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442099" href="#headnote_ref_pq2-dec_442099">[6]</a> <span>Infringement &mdash; Willful </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.16" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.16">&#9658;120.16</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's finding that defendant willfully infringed patent for prosthetic vascular grafts made from expanded polytetrafluoroethylene (ePTFE), since jury heard evidence of 18-year interference between inventor of patent in suit and defendant's plant manager, in which inventor prevailed, which showed that defendant was aware of both patent's existence and inventor's research activities, since defendant relied on same references that had been considered by U.S. Patent and Trademark Office and rejected as non-invalidating, since plaintiff presented substantial evidence that opinion of counsel relied on by defendant was not based on objective perspective, including evidence that bases of alleged invalidity asserted in opinion were directly contradictory to validity arguments defendant presented to PTO when attempting to claim same invention, and that same law firm represented defendant both before and after plaintiff's patent issued, and since defendant's presentation of several defenses at trial does not mean that jury's finding of willfulness lacks sufficient evidentiary basis. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442100" href="#headnote_ref_pq2-dec_442100">[7]</a> <span>Monetary &mdash; Damages &mdash; Patents &mdash; Increased damages </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=510.0507.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="510.0507.07">&#9658;510.0507.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court did not abuse its discretion by awarding double enhanced damages for defendant's willful infringement of patent for prosthetic vascular grafts, since jury's finding of willfulness is supported by substantial evidence, and since district court conducted detailed and exhaustive review of factors considered in determining whether infringer has acted in bad faith, and court's finding that eight out of nine factors favored enhancement of damages, but that three of eight factors weighed only slightly in favor of enhancement, supports court's decision to double, rather than triple, amount of damage award.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442101" href="#headnote_ref_pq2-dec_442101">[8]</a> <span>Monetary &mdash; Attorneys' fees; costs &mdash; Patents &mdash;
Exceptional case </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=510.0905.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="510.0905.03">&#9658;510.0905.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnote_text">
Award of attorneys' fees to prevailing plaintiff is affirmed in action in which jury found willful infringement of patent for prosthetic vascular grafts, since federal district court found that defendant continued to infringe patent despite extensive litigation between parties that defendant repeatedly lost, since district court determined that defendant argued contradictory positions on infringement throughout litigation, and relied on testimony that was not credible, and since district court therefore had sufficient bases for concluding that case was exceptional under 35 U.S.C. &sect;285, and did not abuse its discretion in awarding attorneys' fees and costs.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_442102" href="#headnote_ref_pq2-dec_442102">[9]</a> <span>Monetary &mdash; Damages &mdash; Patents &mdash; Reasonable royalty </span> <a href="http://www.bloomberglaw.com/document/1688765136899/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=510.0507.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="510.0507.03">&#9658;510.0507.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court, in awarding ongoing royalty to plaintiff for defendant's future infringement of patent for prosthetic vascular grafts, did not abuse its discretion by setting royalty rate at 12.5 to 20 percent, depending on type of infringing graft involved, since district court, in setting different rates for different types of grafts, made reasonable and valid assumptions by taking market forces into account, since district court properly determined that ongoing royalty rate should be higher than 10 percent reasonable royalty set by jury in view of changed legal status of parties following verdict, since district court considered other economic factors, including that parties compete directly with respect to surgical grafts, that defendant profits highly from its infringing products, that defendant potentially faces stiffer losses, including permanent injunction, if plaintiff prevails in second lawsuit, and that plaintiff seeks adequate compensation and lacks incentive to accept below-market deal, and since court reasoned that value defendant added to its grafts that are bonded with heparin warranted lower royalty rates on those products.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
[EDITOR'S NOTE: This case is unpublished as indicated by the issuing court.]
  <span CLASS="page_no" data-cite="101 uspq 2d 1643" data-cite-type="ReporterOfDecisions" data-cite-pageno="1643" data-primary-citation="101 U.S.P.Q.2d 1641">[**1643]</span> Appeal from the United States District Court for the
District of Arizona in case <cite>no. 03-CV-0597</cite>, Judge Mary H.
Murguia.
<span CLASS="page_no" data-cite="670 f 3d 1174" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1174" data-primary-citation="670 F.3d 1171">[*1174]</span> </p></div>
<div id="para2" printdualcolumn="true"><p>

</p></div>
<div id="para2" printdualcolumn="true"><p>
  STEVEN C. CHERNY, Kirkland &amp; Ellis, LLP, of New York,
New York, argued for the plaintiffs/counterclaim
defendants-appellees and counterclaim defendant-appellee. With
him on the brief were JOHN C. O'QUINN, NATHAN S. MAMMEN and
WILLIAM H. BURGESS, of Washington,

DC. Of counsel on the brief were GREGORY G. GARRE and
MAXIMILIAN A. GRANT, Latham &amp; Watkins LLP, of Washington,
DC; ANDREW M. FEDERHAR, Fennemore Craig P.C., of Phoenix, of
Arizona; and JOHN L. STRAND, Wolf, Greenfield &amp; Sacks,
P.C., of Boston, Massachusetts. Of counsel was AMANDA HOLLIS,
Kirkland &amp; Ellis LLP, of Chicago, Illinois.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  RICHARD G. TARANTO, Farr &amp; Taranto, of Washington, DC,
argued for the defendant/counterclaimant-appellant. Of counsel
on the brief were DAVID H. PFEFFER, <span CLASS="page_no" data-cite="670 f 3d 1175" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1175" data-primary-citation="670 F.3d 1171">[*1175]</span> HARRY C. MARCUS, JAMES W.
GOULD, STEVEN M. PURDY and JOSEPH A. FARCO., Locke, Lord,
Bissell &amp; Liddell, LLP, of New York, New York; MATTHEW K.
BLACKBURN, of San Francisco, California; and WILLIAM J.
MALEDON, Osborn Maledon, P.A., of Phoenix, Arizona; JOHN S.
CAMPBELL, W.L. Gore &amp; Associates, Inc., of Newark,
Delaware.
</p></div>
<div id="para2" printdualcolumn="true"><p>

</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before NEWMAN, GAJARSA,<a HREF="#fn*00" name="fnref_fn*00">[fn*]</a> and LINN, <i>Circuit</i>
<i>Judges.</i>
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn*00" name="fn*00">[fn*]</a></span> Circuit Judge Gajarsa assumed senior status on July 31,
2011.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion for the court filed by <i>Circuit Judge</i> GAJARSA.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Dissenting opinion filed by <i>Circuit Judge</i> NEWMAN.
</p></div>
<div id="para2" printdualcolumn="true"><p>

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  GAJARSA, <i>Circuit Judge.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This has been a long and arduous journey for the parties in
this litigation, but this should be the final curtain of the
saga, which commenced in 1974 with the filing of the patent
application that eventually matured as <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">U.S. Patent
No. 6,436,135</a> ("<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">'135 patent</a>"). In this patent infringement action,
W.L. Gore &amp; Associates, Inc. ("Gore") appeals the United
States District Court for the District of Arizona's judgment,
after a jury verdict, that (1) found

the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> willfully infringed and not invalid for
improper inventorship, anticipation, obviousness, or lack of
written description, and (2) awarded enhanced damages,
attorneys' fees and costs, and an ongoing royalty in favor of
Bard Peripheral Vascular, Inc. and David Goldfarb
(collectively, "Bard"). <i>Bard Peripheral Vascular, Inc. v.</i>
<i>W.L. Gore &amp; Assocs., Inc.</i> ("<i>Final Judgment</i>"),
<cite>No. 03-CV-0597</cite> (D. Ariz. Aug. 24, 2010), E C F No. 1047.
Because we find that there is substantial evidence to support
the jury's verdict of no improper inventorship, anticipation,
obviousness, or lack of written description and of willful
infringement, and the district court did not abuse its
discretion in awarding enhanced damages, attorneys' fees and
costs, and an ongoing royalty, we affirm the judgment.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The technology in this case involves prosthetic vascular grafts
that are fabricated from highly-expanded
polytetrafluoroethylene ("ePTFE"). `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> col.1 ll.3-5.
The grafts are used to bypass or replace blood vessels to
assure adequate and balanced blood flow to particular parts of
the body. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/1?citation=usp%206436135&amp;summary=yes#jcite">Id</a>.</i> col.1 ll.6-7.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the early 1970s, <span CLASS="page_no" data-cite="2012 bl 32360 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> when the invention was made, ePTFE
  was produced as tubes that had a structure

  consisting of solid nodes of PTFE connected by thin
  PTFE fibrils. The distance between the nodes is
  referred to as the fibril length [or the internodal
  distance]. This distance is important to the
  suitability of the ePTFE material for use as a
  vascular graft.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper v. Goldfarb</i> ("<i>Cooper II</i>"),
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d 1378</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">1381</a> (Fed. Cir. 2001); <i>see also Cooper v.</i>
<i>Goldfarb</i> ("<i>Cooper I<span CLASS="page_no" data-cite="101 uspq 2d 1644" data-cite-type="ReporterOfDecisions" data-cite-pageno="1644" data-primary-citation="101 U.S.P.Q.2d 1641">[**1644]</span> </i>"), <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d 1321</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">1324</a>
(Fed. Cir. 1998). Gore sells ePTFE under the brand name "Gore-Tex."
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1324</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, entitled "Prosthetic Vascular Graft," was
filed on October 24, 1974 and issued nearly twenty-eight years
<span CLASS="page_no" data-cite="670 f 3d 1176" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1176" data-primary-citation="670 F.3d 1171">[*1176]</span> later on August 20, 2002. `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> at [54], [22], [45]. The
`<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> discloses a graft "formed from a small bore tube of
polytetrafluoroethylene which has been heated, expanded and
sintered so as to have a microscopic superstructure of
uniformly distributed nodes interconnected by fibrils. . . ."
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.3 ll.41-44. A major objective of the claimed
invention is providing "a homogeneously porous vascular
prosthesis" with "small nodes interconnected by extremely fine
fibrils to form an open superstructure which will allow
uniform, controlled transmural cellular ingrowth and thereby
assure the establishment and maintenance of a thin, viable
neointima as well as firm structural integration of the graft
into the body." <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.3 ll.27-34.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bard asserts that Gore infringes claims 20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135
patent</a>, of which independent claim 20 is representative:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  20. An artificial vascular prosthesis comprising
  expanded, porous, polytetrafluorocthylene [sic] having
  a microstructure consisting of nodes inter-connected
  by fibrils which permits <i>tissue in-growth</i>,

  wherein an average <i>distance between nodes</i> is
  not less than about 6 microns and is small enough to
  prevent transrmural [sic] blood flow.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.12 ll.1-6 (emphases added). Claims 21 to 24,
which depend from claim 20, claim an upper limit on the average
distance between the nodes from about 80 to about 200 microns.
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.12 ll.7-18. Independent claims 25 to 27 claim
that the average distance between the nodes is about 6 to about
80 microns. Claims 25 and 26 also specify "a wall thickness
greater than about 0.2 millimeters and less than about 0.8
millimeters." <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.12 ll.21-22, 28-29. Claim 26
further adds the limitation of "an average density in the range
of between about 0.2 and 0.5 grams per millimeter."
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">Id</a>.</i> col.12 ll.30-31.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The prior art at issue in this appeal includes two articles,
one by Dr. Jay Volder and one by Dr. Hiroshi Matsumoto.
<i>See</i> Jay G. R. Volder et al., <i>A-V Shunts Created in</i>
<i>New Ways</i>, Transactions, American Society for Artificial
Internal Organs, vol. XIX, Apr. 8-9, 1973, at 38-42 ("Volder");
H. Matsumoto et al., <i>A New Vascular Prosthesis for a Small</i>
<i>Caliber Artery</i>, Surgery, vol. 74, no. 4, Oct. 1973,
at 519-23 ("Matsumoto"). Both publications were considered by the
examiner at the United States Patent and Trademark Office
("PTO") during the prosecution of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> and are
listed on the first page of the patent-in-suit. `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> at
[56].
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The factual history of this case has been discussed in a
previous decision of this court:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [Peter] Cooper was the Plant Manager of [Gore's]
  Flagstaff, Arizona facility, and primarily was
  involved <span CLASS="page_no" data-cite="2012 bl 32360 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> in making ePTFE tubes. Cooper provided the
  tubes to various researchers, who evaluated their
  suitability for vascular grafts. During the

  course of his work, Cooper discovered that material
  from ePTFE tubes with fibril lengths . . . [of about 5
  to 100 microns] was suitable for use in vascular
  grafts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During the same period, Goldfarb was Director of
  Research and Clinical Staff Surgeon at the Arizona
  Heart Institute [("AHI")], and was conduct-ing
  research on artificial vascular grafts. Between
  February and April of 1973, Cooper sent Goldfarb a
  number of ePTFE tubes to use in his research. Although
  Cooper intended that Goldfarb use the tubes for
  vascular grafts, Cooper did not have any right of
  control over Goldfarb's research, and Goldfarb was not
  required to use the tubes supplied by Cooper or to
  perform <span CLASS="page_no" data-cite="670 f 3d 1177" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1177" data-primary-citation="670 F.3d 1171">[*1177]</span> his experiments in any particular way.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Goldfarb conducted a series of experiments involving
  21 grafts made from the tubes Cooper provided. On June
  13, 1973, the graft labeled "2-73 RF," which came
  from Lot 459-04133-9 provided by Cooper, was
  determined to be a successful implant in a dog.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1381</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> was previously the subject of an interference
proceeding between Cooper and Goldfarb at the Board of Patent
Appeals and Interferences ("Board"), Interference <cite>No. 101,100</cite>
("Interference"). On April 2, 1974, Cooper filed <cite>Patent
Application No. 05/457,711</cite> claiming the use of ePTFE as a
vascular graft. <i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1325</a>. On October
24, 1974, Goldfarb filed Patent Application No. 05/517,415 also
claiming the use of

ePTFE as a vascular graft. <i>Id.</i> at 1326. On
September 19, 1983, the PTO declared an interference between
the two patent applications <span CLASS="page_no" data-cite="101 uspq 2d 1645" data-cite-type="ReporterOfDecisions" data-cite-pageno="1645" data-primary-citation="101 U.S.P.Q.2d 1641">[**1645]</span> with Cooper as the senior party and
Goldfarb as the junior party. <i>Id.</i> The only count,
which is "the Board's description of the interfering subject
matter that sets the scope of admissible proofs on priority,"
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X10NTLI003?jcsearch=37%20cfr%2041%20201&amp;summary=yes#jcite">37 C.F.R. &sect; 41.201</a>, from the Interference relevant to this
case states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An artificial vascular prosthesis comprising expanded,
  porous, polytetraflouroethylene [sic] having a
  microstructure consisting of nodes interconnected by
  fibrils which permits tissue in-growth, wherein said
  fibrils are above about 5 microns up to 100 microns in
  length.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1326</a>. The Board awarded priority
of invention to Goldfarb because Goldfarb established that he
had reduced the invention to practice before Cooper.
<i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1326-27</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court affirmed "the Board's determination that Goldfarb
had conceived the invention and reduced it to practice by July
of 1973." <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1331</a>. This court also, however,
determined that the Board erred "by failing to consider whether
Goldfarb's efforts inure to the benefit of Cooper," and
remanded the case for the Board to consider that issue.
<i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1333</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal for the second time, this court explained that Cooper
conceived the invention, but only after sending to Goldfarb the
tubes which Goldfarb used to conceive the invention and reduce
it to practice. <i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1381</a>. Cooper
could not have known that the tubes sent to Goldfarb met the
claim limitations when he sent them. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20F.3d%201378&amp;summary=yes#jcite">Id</a>.</i> Additionally,
Cooper neither communicated his finding to Goldfarb before
Goldfarb made the invention nor did he exercise diligence in an
attempt to

reduce the invention to practice. <span CLASS="page_no" data-cite="2012 bl 32360 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20F.3d%201378&amp;summary=yes#jcite">Id. at 1381-83</a>.
Therefore, this court found that "Cooper has not established
that he contemporaneously appreciated that the material tested
by Goldfarb met the fibril length limitation of the
interference count, and has not established that Goldfarb's
knowledge of the material's fibril lengths inured to his
benefit." <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20F.3d%201378&amp;summary=yes#jcite">Id. at 1381-82</a>. Accordingly, this court
affirmed the Board's decision that "the relationship between
Cooper and Goldfarb was such that Goldfarb's work did not inure
to Cooper's benefit" and priority of invention was awarded to
Goldfarb. <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20F.3d%201378&amp;summary=yes#jcite">Id. at 1380</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   C.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On March 28, 2003, Bard filed suit against Gore for
infringement of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>. After a seventeen-day trial,
on December 11, 2007, a jury found the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> valid and
willfully infringed by Gore. <i>Bard Peripheral Vascular, Inc.</i>
<i>v. W.L. Gore &amp; Assocs., Inc.</i> ("<i>Verdict</i>
<i>Form</i>"), <cite>No. 03-CV-0597</cite> (D. Ariz. Dec. 11, 2007), <span CLASS="page_no" data-cite="670 f 3d 1178" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1178" data-primary-citation="670 F.3d 1171">[*1178]</span> ECF
No. 771. More specifically, the jury found that the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> was
not invalid for improper inventorship, anticipation,
obviousness, or lack of written description. <i></i><cite>Id.
at 16-19</cite>. The jury awarded Bard lost profits in the amount of
$102,081,578.82 and reasonable royalties in the amount of
$83,508,292.20, and set a reasonable royalty rate of 10%.
<i></i><cite>Id. at 22-23</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In what it deemed "the most complicated case th[e district]
court has presided over," <i>Bard Peripheral Vascular, Inc. v.</i>
<i>W.L. Gore &amp; Assocs., Inc.</i> ("<i>License</i>"),
<cite>No. 03-CV-0597</cite>, slip op. at 1 (D. Ariz. July 21, 2010), ECF
No. 1057, the court denied Gore's motions for judgment as a matter
of law on inventorship, anticipation, obviousness, written
description, and willfulness. <i>Bard Peripheral Vascular,</i>
<i>Inc. v. W.L. Gore &amp; Assocs., Inc.</i> ("<i>Post-Trial</i>
<i>I</i>"), <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d 1083</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">1099</a> (D. Ariz. 2008); <i>Bard</i>
<i>Peripheral</i>

<i>Vascular, Inc. v. W.L. Gore &amp; Assocs., Inc.</i>
("<i>Obviousness I</i>"), <cite>No. 03-CV-0597</cite>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">2008 BL 158898</a>], 2008 WL 2954187, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*6&amp;summary=yes#jcite">at
*6</a> (D. Ariz. July 29, 2008). The court also denied Gore's
renewed motions for judgment as a matter of law on those
issues. <i>Bard Peripheral Vascular, Inc. v. W.L. Gore</i>
<i>&amp; Assocs., Inc.</i> ("<i>Post-Trial II</i>"), <cite>No. 03-CV-0597</cite>,
[<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGA003?jcsearch=2009%20BL%2070609&amp;summary=yes#jcite">2009 BL 70609</a>], 2009 WL 886514, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGA003?jcsearch=at%20*12-13&amp;summary=yes#jcite">at *12-13</a> (D. Ariz. Mar. 31, 2009); <i>Bard</i>
<i>Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., Inc.</i>
("<i>Obviousness II</i>"), <cite>No. 03-CV-0597</cite>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*7&amp;summary=yes#jcite">at
*7</a> (D. Ariz. Mar. 31, 2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court awarded Bard enhanced damages by a factor of
two, doubling Bard's award from the $185,589,871.02 jury
verdict amount to $371,179,742.04. <i>Bard Peripheral</i>
<i>Vascular, Inc. v. W.L. Gore &amp; Assocs., Inc.</i>
("<i>Damages</i>"), <cite>No. 03-CV-0597</cite>, slip op. at 20, 23
(D. Ariz. Mar. 31, 2009), ECF No. 951. The court also awarded Bard
its attorneys' fees and non-taxable costs in the amount of $19
million. <i></i><cite>Id. at 23</cite>. Additionally, the court denied
Bard's motion for a permanent injunction, but granted Bard's
alternative motion for the imposition of an ongoing royalty.
<i>Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs.,</i>
<i>Inc.</i> ("<i>Injunction</i>"), <cite>No. 03-CV-0597</cite>,
<cite>2009 WL 920300</cite>, <cite>at *4-10</cite> (D. Ariz. Mar. 31, 2009). The court awarded
Bard an ongoing royalty with a range of royalty rates from
12.5% to 20% for Gore's various types of infringing
grafts.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> <i>License</i>, slip op. at 15-16.
<span CLASS="page_no" data-cite="101 uspq 2d 1646" data-cite-type="ReporterOfDecisions" data-cite-pageno="1646" data-primary-citation="101 U.S.P.Q.2d 1641">[**1646]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court entered an amended final judgment on August
24, 2010, and Gore timely appealed on August 25, 2010.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court had jurisdiction under
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEIMV6003?jcsearch=28%20U.S.C.%20%201338(a)&amp;summary=yes#jcite">28 U.S.C. &sect; 1338</a>(a), and we have appellate jurisdiction under
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review denial of post-trial motions for judgment as a matter
of law under the applicable regional circuit law, the Ninth
Circuit in this case. <i>See Revolution Eyewear, Inc. v. Aspex</i>
<i>Eyewear, Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1B1LRQ003?jcsearch=563%20f%203d%201358&amp;summary=yes#jcite">563 F.3d 1358</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1B1LRQ003?jcsearch=563%20f%203d%201358&amp;summary=yes#jcite">1370</a> (Fed. Cir. 2009). The
Ninth Circuit reviews a district court's denial of motions <span CLASS="page_no" data-cite="2012 bl 32360 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> for
judgment as a matter of law <i>de novo. Janes v. Wal-Mart</i>
<i>Stores Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X4IRKK?jcsearch=279%20f%203d%20883&amp;summary=yes#jcite">279 F.3d 883</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X4IRKK?jcsearch=279%20f%203d%20883&amp;summary=yes#jcite">886</a> (9th Cir. 2002). A "jury's
verdict must be upheld if it is supported <span CLASS="page_no" data-cite="670 f 3d 1179" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1179" data-primary-citation="670 F.3d 1171">[*1179]</span> by substantial
evidence, . . . even if it is also possible to draw a contrary
conclusion." <i>Pavao v. Pagay</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XE7IIR?jcsearch=307%20f%203d%20915&amp;summary=yes#jcite">307 F.3d 915</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XE7IIR?jcsearch=307%20f%203d%20915&amp;summary=yes#jcite">918</a> (9th
Cir. 2002). Substantial evidence is "relevant evidence as
reasonable minds might accept as adequate to support a
conclusion." <i>Three Boys Music Corp. v. Bolton</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3IR9M?jcsearch=212%20f%203d%20477&amp;summary=yes#jcite">212 F.3d 477</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3IR9M?jcsearch=212%20f%203d%20477&amp;summary=yes#jcite">482</a> (9th Cir. 2000) (citation omitted). The Ninth
Circuit "disregard[s] all evidence favorable to the moving
party that the jury is not required to believe, and may not
substitute its view of the evidence for that of the jury."
<i>Johnson v. Paradise Valley Unified Sch. Dist.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50S3R?jcsearch=251%20f%203d%201222&amp;summary=yes#jcite">251 F.3d 1222</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50S3R?jcsearch=251%20f%203d%201222&amp;summary=yes#jcite">1227</a> (9th Cir. 2001) (internal quotation marks and
citations omitted). The court will not "weigh the

evidence or assess the credibility of witnesses in
deter-mining whether substantial evidence exists." <i>Landes</i>
<i>Constr. Co. v. Royal Bank of Can.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XAFI4B?jcsearch=833%20f%202d%201365&amp;summary=yes#jcite">833 F.2d 1365</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XAFI4B?jcsearch=833%20f%202d%201365&amp;summary=yes#jcite">1371</a>
(9th Cir. 1987) (citations omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review a district court's "award of enhanced damages and
attorney fees under an abuse of discretion standard." <i>ACCO</i>
<i>Brands, Inc. v. ABA Locks Mfrs. Co.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17LHQQ003?jcsearch=501%20f%203d%201307&amp;summary=yes#jcite">501 F.3d 1307</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17LHQQ003?jcsearch=501%20f%203d%201307&amp;summary=yes#jcite">1312</a>
(Fed. Cir. 2007) (citation omitted). We also review an award of
a royalty-bearing license and refusal to issue a permanent
injunction for abuse of discretion. <i>On Demand Mach. Corp.</i>
<i>v. Ingram Indus., Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X14LUI6003?jcsearch=442%20f%203d%201331&amp;summary=yes#jcite">442 F.3d 1331</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X14LUI6003?jcsearch=442%20f%203d%201331&amp;summary=yes#jcite">1337</a> (Fed. Cir.
2006). A district court abuses its discretion when "its
decision is based on clearly erroneous findings of fact, is
based on erroneous interpretations of the law, or is clearly
unreasonable, arbitrary or fanciful." <i>Cybor Corp. v. FAS</i>
<i>Techs., Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">138 F.3d 1448</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">1460</a> (Fed. Cir. 1998) (en
banc) (citation omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Gore contends that the jury's verdict on the inventor-ship,
anticipation, obviousness, written description, and willful
infringement issues was not supported by substantial evidence
and the district court abused its discretion regarding the
issues of enhanced damages, attorneys' fees and costs, and
ongoing royalties. For the following reasons, we disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   A.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Inventorship is "a question of law that we review <i>de</i>
<i>novo</i>, based on underlying facts which we review for clear
error." <i>Univ. of Pittsburgh of the Commonwealth Sys. of</i>
<i>Higher Educ. v. Hedrick</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BC6D2003?jcsearch=573%20f%203d%201290&amp;summary=yes#jcite">573 F.3d 1290</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BC6D2003?jcsearch=573%20f%203d%201290&amp;summary=yes#jcite">1297</a> (Fed. Cir.
2009). When this court reviews the denial of post-verdict
motions for judgment as a matter of law on "mixed question[s]
of law and fact given to a jury . . ., we must sustain the
jury's conclusion unless the jury was not presented with
substantial evidence to support any set of

implicit findings sufficient under the law to arrive at its
conclusion." <i>Eli Lilly &amp; Co. v. Aradigm Corp.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEQ9KA?jcsearch=376%20f%203d%201352&amp;summary=yes#jcite">376 F.3d 1352</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEQ9KA?jcsearch=376%20f%203d%201352&amp;summary=yes#jcite">1362</a> (Fed. Cir. 2004) (citation omitted) (calling
substantial evidence that which "a reasonable mind might accept
as adequate to support a conclusion").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Section <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEJ000003?jcsearch=35%20U.S.C.%20%20116&amp;summary=yes#jcite">116</a> of Title 35 of the United States Code states that
"[w]hen an invention is made by two or more persons jointly,
they shall apply for patent jointly." "The inventors as named
in an issued patent are presumed to be correct. Thus, a party
alleging non joinder must meet the heavy burden of proving its
case by clear and convincing evidence." <i>Natron Corp. v.</i>
<i>Schukra U.S.A., Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1AM264003?jcsearch=558%20f%203d%201352&amp;summary=yes#jcite">558 F.3d 1352</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1AM264003?jcsearch=558%20f%203d%201352&amp;summary=yes#jcite">1356</a> (Fed. Cir. 2009)
(citations omitted). A person is "a joint inventor only if he
contributes to the conception of the <span CLASS="page_no" data-cite="2012 bl 32360 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> claimed invention."
<i>Eli Lilly</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEQ9KA?jcsearch=376%20f%203d%201352&amp;summary=yes#jcite">376 F.3d at 1359</a> (citations omitted).
Conception "requires that the inventor appreciate that which he
has invented." <i>Invitrogen Corp. v. Clontech Labs.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X13JO6U003?jcsearch=429%20f%203d%201052&amp;summary=yes#jcite">429 F.3d 1052</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X13JO6U003?jcsearch=429%20f%203d%201052&amp;summary=yes#jcite">1063</a> (Fed. Cir. 2005). Joint inventorship,
therefore, arises only "when collaboration or concerted effort
occurs &mdash; that is, when the inventors have some open line
of communication <span CLASS="page_no" data-cite="670 f 3d 1180" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1180" data-primary-citation="670 F.3d 1171">[*1180]</span> during or in temporal proximity to their
inventive efforts." <i>Eli Lilly</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEQ9KA?jcsearch=376%20f%203d%201352&amp;summary=yes#jcite">376 F.3d at 1359</a>.
Additionally, a joint inventor must
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) contribute in some significant manner to the
  conception or reduction to practice of <span CLASS="page_no" data-cite="101 uspq 2d 1647" data-cite-type="ReporterOfDecisions" data-cite-pageno="1647" data-primary-citation="101 U.S.P.Q.2d 1641">[**1647]</span> the invention,
  (2) make a contribution to the claimed invention that
  is not insignificant in quality, when that
  contribution is measured against the dimension of the
  full invention, and (3) do more than merely explain to
  the real inventors well-known concepts and/or the
  current state of the
art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Pannu v. Iolab Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54V38?jcsearch=155%20f%203d%201344&amp;summary=yes#jcite">155 F.3d 1344</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54V38?jcsearch=155%20f%203d%201344&amp;summary=yes#jcite">1351</a> (Fed. Cir.
1998). Therefore, in order to prevail at trial, Gore had to

prove by clear and convincing evidence that Cooper
contributed to Dr. Goldfarb's conception of the internodal
distances in a significant way.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury found that the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> was not invalid for
improper inventorship by finding that Cooper and Goldfarb were
not joint inventors of the claimed invention.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> <i>Verdict</i>
<i>Form</i>, at 18. The district court determined that "Gore
failed to present sufficient evidence to show that a reasonable
jury could not have found the patent valid notwithstanding
Gore's claims of improper inventor-ship" and denied Gore's
motion for judgment as a matter of law on the issue.
<i>Post-Trial I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d at 1094</a>. On appeal, Gore
argues that Cooper's contributions to the conception of the
invention were significant and make him a joint inventor. We
hold that Bard presented substantial evidence for the jury to
find that Goldfarb and Cooper were not joint inventors because
Cooper did not communicate to Goldfarb that the internodal
distance was the key to creating successful grafts, and,
therefore, the jury could have reasonably concluded that
Cooper's collaboration with Goldfarb did not contribute to the
conception of the invention in a significant manner.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442094" href="#headnote_pq2-dec_442094">[1]</a> In an appeal from the Interference, this court determined that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [the evidence] do[es] not indicate that Cooper
  expected that the ePTFE material that was to be tested
  by Goldfarb had the fibril lengths required by the
  interference count, or that Cooper submitted the
  material to Goldfarb for a determination of

  its fibril lengths. As noted in <i>Cooper I</i>, . . .
  Cooper was focusing on the porosity of the material
  at that time, not its fibril length. <i>Cooper</i>
  <i>I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1324</a>. Indeed, Cooper admits that,
  even after he conceived the importance of fibril
  length, he did not convey that information to
  Goldfarb. He also admits that he did not ask Goldfarb
  to <i>use grafts</i> with fibril lengths required by
  the interference count, or to determine the fibril
  lengths of successful grafts. While Cooper was not
  required to communicate his conception to Goldfarb,
  <i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1332</a>, his failure to
  convey any in-formation or requests regarding fibril
  length prevents Goldfarb's determination of the fibril
  lengths of the material from inuring <span CLASS="page_no" data-cite="2012 bl 32360 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> to his benefit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [N]o evidence of record indicates that Cooper knew the
  fibril lengths of the material tested by Goldfarb at
  the relevant time, i.e., prior to Goldfarb's
  reduction to practice in 1973.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1385</a>. This lack of
communication and utter lack of understanding of what would
make a successful graft is substantial evidence in support of
<span CLASS="page_no" data-cite="670 f 3d 1181" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1181" data-primary-citation="670 F.3d 1171">[*1181]</span> the jury's verdict implicitly finding that Cooper's
contribution was insignificant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Gore argues that Cooper "conveyed [the internodal
distance] physically by making and sending the invention
embodiment to Goldfarb," it admits that "Cooper did not
verbally convey the internodal distance." Appellant's Br. 46.
Additionally, Goldfarb testified at trial that the various
tubes Gore sent to him looked the same to the naked eye, but
each tube was different, and

that each individual tube's microstructure varied along the
length of the tube. J.A. 9370-72, 76. Goldfarb personally
selected the most promising sections for implantation. [<cite>Id</cite>].
Goldfarb also testified that after an initial set of
implantations, he gave a Gore employee specifications of what
might make a more successful graft, including specific
internodal distances. J.A. 9398-99. Therefore, the jury could
have reasonably determined that "physically conveying" the
undifferentiated tubes to Goldfarb was an insignificant
contribution to the conception of the importance of internodal
distance when weighed against Goldfarb's personal selections
and directions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As further evidence of the insignificance of Cooper's
contribution, Cooper previously testified in the Interference
that he did not provide Goldfarb information about the GORE-TEX
structure "in any great detail" when they met. J.A. 23112. He
also testified that he later resorted to taking Goldfarb's
slides to learn what variables in the grafts were important in
producing good results. J.A. 36993-94. Also in the
Interference, former Gore employee Richard Mendenhall testified
that "there was no <span CLASS="page_no" data-cite="101 uspq 2d 1648" data-cite-type="ReporterOfDecisions" data-cite-pageno="1648" data-primary-citation="101 U.S.P.Q.2d 1641">[**1648]</span> discussion of substance" at a meeting with
Cooper and Goldfarb, and that it was Goldfarb who explained to
Cooper "the characteristics that were ideal for the synthetic
artery," not the other way around. J.A. 22648, 22642. Finally,
in the present case, Goldfarb testified that, with the
exception of a statistician's suggestion to randomize the
placement of certain grafts, no one from Gore gave him any
instruction regarding how to set up his experiments, including
what types of grafts to use, what characteristics to look for,
and what range of variables would produce a successful graft.
J.A. 31638-40. Notably, Gore employee Dan Detton's previous
deposition testimony was read into the record stating that
Cooper never made grafts, never extruded tubing that was used
to make grafts, and did not

contribute to the design of the structure that Goldfarb
made. When asked if Cooper contributed to the design of the
structure made by Goldfarb, Detton said "you could generally
count on whatever he said as being probably 180 degrees from
what was correct."<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In addition to evidence of Cooper's failure <span CLASS="page_no" data-cite="2012 bl 32360 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> to communicate the
internodal distance to Goldfarb, or make any contribution to
the conception of internodal distance, Bard also presented
evidence of Goldfarb's control over his experiments. A Gore
"Trip Report" stated that "Dr. <span CLASS="page_no" data-cite="670 f 3d 1182" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1182" data-primary-citation="670 F.3d 1171">[*1182]</span> Goldfarb is starting an
evaluation of synthetic materials suitable for a bypass graft
and is willing to include GORE-TEX in <i>his</i> study." J.A.
39694 (emphasis added).<a HREF="#fn500" name="fnref_fn500">[fn5]</a> A February 14, 1973 letter from
Cooper to Goldfarb explained that enclosed were "a variety of
sizes of GORETEX tubes for <i>your</i> animal artery
prosthetic experiments." J.A. 41235 (emphasis added). Also,
Goldfarb testified that Cooper "had very little contact with
[him],"

and that it was Mendenhall who first contacted him
regarding the use of ePTFE in medicine. J.A. 9409, 31564.
Finally, Cooper himself wrote letters to another doctor stating
that "[a]ny success at this point in time is the direct result
of the AHI [i.e., Goldfarb's,] efforts," and that the "AHI has,
in a well-organized, productive fashion, described, with a fair
degree of accuracy, the specific structure necessary for a
viable vascular graft."<a HREF="#fn600" name="fnref_fn600">[fn6]</a> J.A. 29587, 35493.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, although Gore attempts to recast its argument from
inurement in the Interference to joint inventorship in the
present case, Gore's argument remains unchanged and there is
still no evidence that Cooper either recognized or appreciated
the critical nature of the internodal distance and communicated
that key requirement to Goldfarb before Goldfarb reduced the
invention to practice. Accordingly, substantial evidence
supports the jury's finding that the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> is not invalid
for improper inventorship, and the district court did not err
in denying Gore's motion for judgment as a matter of law on the
issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is apparent that the dissent reaches its opposite conclusion
by ignoring the applicable standard of review and giving
insufficient weight to the jury's verdict. By citing only to
the limited facts that support Gore's case and relying on a
mistaken understanding of the invention at issue, the dissent
fails to "disregard all evidence favorable to the moving party
that the jury is not required to believe" and intentionally,
but impermissibly, "substitute[s] its view of the evidence for
that of the jury."

<i>Johnson</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50S3R?jcsearch=251%20f%203d%201222&amp;summary=yes#jcite">251 F.3d at 1227</a> (internal citations and
quota-tion marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As to the facts, the dissent states that Cooper conceived the
invention and Gore "disclosed [it] to Goldfarb", Dissent at 17
&amp; 19, while Goldfarb did little more than "test" the
material at Cooper's direction. Dissent at 1-2. It states that
"Gore possessed" the invention before Goldfarb, Dissent at 14,
and credits Gore's argument that Cooper "was at least a joint
inventor." Dissent at 17. The dissent concludes that the
"verdict is against the weight of the evidence." Dissent at 20.
Ignoring the problem inherent in the dissent's misstatement of
the applicable standard of review, we note that this court has
previously concluded that Goldfarb independently conceived and
reduced the invention to practice. <i>Cooper I</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1330-31</a>. Cooper conceived of the invention only after
sending the tubes to Goldfarb and <span CLASS="page_no" data-cite="2012 bl 32360 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> never communicated that
conception <span CLASS="page_no" data-cite="101 uspq 2d 1649" data-cite-type="ReporterOfDecisions" data-cite-pageno="1649" data-primary-citation="101 U.S.P.Q.2d 1641">[**1649]</span> to Goldfarb. <i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1385</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, as to the invention, the dissent states that Goldfarb
could not be the sole inventor because Gore "possessed" the
invention before Goldfarb, and Cooper suggested ePTFE as a
vascular graft to Goldfarb. Dissent at 14-15. (citing to
<i>Shatterproof Glass Corp. v. Libbey-Owens Ford Co.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20f%202d%20613&amp;summary=yes#jcite">758 F.2d 613</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20f%202d%20613&amp;summary=yes#jcite">624</a> (Fed. Cir. 1985) (<span CLASS="page_no" data-cite="670 f 3d 1183" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1183" data-primary-citation="670 F.3d 1171">[*1183]</span> find-ing "substantial evidence
on which a reasonable jury could have found that the inventors
were correctly named" despite conflicting trial
testimony)).<a HREF="#fn700" name="fnref_fn700">[fn7]</a> However,

this court has explained previously that "a person will not
be a co-inventor if he or she does no more than explain to the
real inventors concepts that are well known and the current
state of the art." <i>Fina Oil &amp; Chem. Co. v Ewen</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3L8PJ?jcsearch=123%20f%203d%201466&amp;summary=yes#jcite">123 F.3d 1466</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3L8PJ?jcsearch=123%20f%203d%201466&amp;summary=yes#jcite">1473</a> (Fed. Cir. 1997) (internal citations
omitted). "[T]o be a joint inventor, an individual must make a
contribution to the conception of the claimed invention that is
not insignificant in quality, when that contribution is
measured against the dimension of the full invention."
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3L8PJ?jcsearch=123%20F.3d%201466&amp;summary=yes#jcite">Id</a>.</i> In this case, Gore did know about ePTFE before
Goldfarb, but the potential use of ePTFE as a vascular graft
was not a new concept and any suggestion by Cooper to use the
material was insignificant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Rather than the idea of using ePTFE as a graft, the claimed
invention in this case is a vascular prosthesis made from ePTFE
having a very specific range of distances between nodes, which
are connected by fibrils. <i>See, e.g.</i>, `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=USP%206436135&amp;summary=yes#jcite">135 patent</a>
col.12 ll.1-6; <i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1381</a>. Before
Goldfarb made his invention, other doctors had tried to use
ePTFE as a small bore vascular graft, but none understood why
apparently identical grafts would often perform differently
when implanted. [J.A. 35044, 41829, 46193, 49746]. Goldfarb was
the first person to discover that a specific internodal
distance was the determining factor in graft success and reduce
that knowledge to practice. <i>Cooper II</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1380</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent points to letters detailing the results of the
experiments by Drs. Sharp and Kelly, Dissent at 5-7, which show
some patent ePTFE grafts, as support for the conclusion that
Goldfarb could not be the sole inventor.<a HREF="#fn800" name="fnref_fn800">[fn8]</a> However, this
court previously considered those letters

and found that they have no effect on Goldfarb's
inventor-ship. As to the Sharp experiment, this court
previously concluded that the grafts successfully used by Sharp
were not shown to have the same fibril lengths as those in
Goldfarb's invention. <i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1328-29</a>.
As to Kelly's experiment, the dissent neglects to mention that
although the grafts used fell within the claim limitations of
Goldfarb's invention, Cooper considered Kelly's results to be a
failure.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1325</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=1328&amp;summary=yes#jcite">1328</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Cooper never shared whatever knowledge he had about internodal
distances with Goldfarb. Instead, Cooper's contribution to
Goldfarb's invention can be summarized as handing Goldfarb an
undifferentiated selection of ePTFE tubes, some of which turned
out to be suitable for use as a graft. Because Cooper did
little more <span CLASS="page_no" data-cite="670 f 3d 1184" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1184" data-primary-citation="670 F.3d 1171">[*1184]</span> than share with Goldfarb what was already well
known, the jury had substantial evidence to find that Cooper's
contribution was not significant enough <span CLASS="page_no" data-cite="2012 bl 32360 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> to make him a joint
inventor and we must defer to that finding.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> <i>See,</i>
<i>e.g., Hess v. Advanced Cardiovascular Sys.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X37H09?jcsearch=106%20f%203d%20976&amp;summary=yes#jcite">106 F.3d 976</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X37H09?jcsearch=106%20f%203d%20976&amp;summary=yes#jcite">981</a> (Fed. Cir. 1997) (stating that "doing nothing more than
explaining

to the inventors what the then state of the art was and
supplying a product to them for use in their invention" does
not automatically make one a joint inventor).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   B.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Anticipation is "a question of fact that we review for
substantial evidence when tried to a jury." <i>Orion IP, LLC</i>
<i>v. Hyundai Motor Am.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1D87O8003?jcsearch=605%20f%203d%20967&amp;summary=yes#jcite">605 F.3d 967</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1D87O8003?jcsearch=605%20f%203d%20967&amp;summary=yes#jcite">974</a> (Fed. Cir. 2010)
(<span CLASS="page_no" data-cite="101 uspq 2d 1650" data-cite-type="ReporterOfDecisions" data-cite-pageno="1650" data-primary-citation="101 U.S.P.Q.2d 1641">[**1650]</span> citation omitted). The jury found that claims 20 to 27 of the
`<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> were not invalid for anticipation by Matsumoto.
<i>Verdict Form</i>, at 16. The district court determined
that "the evidence establishes that the 1973 Matsumoto
article was not enabling, as neither Gore nor any of the other doctors
with whom Gore was working, could determine the structure
disclosed in the Matsumoto article or replicate Matsumoto's
results." <i>Post-Trial I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d at 1092</a>. The
court cited the trial testimony of Gore's own fact witness, Dan
Detton, who "stated that `you couldn't figure anything' from
the Matsumoto article `because the article itself did not
define anything.'" <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20F.%20Supp.%202d%201083&amp;summary=yes#jcite">Id</a>.</i> (internal citation omitted).
Thus, the court found that Gore "failed to establish that a
reasonable jury would not have a legally sufficient evidentiary
basis to find for [Bard]" and denied Gore's motion for judgment
as a matter of law on anticipation. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20F.%20Supp.%202d%201083&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In Matsumoto, "vascular grafts of expanded
polytetrafluoroethylene . . . 3 mm. in internal diameter and 3
to 5 cm. in length, were inserted between the dissected femoral
arteries in dogs" and the "patency rates of the grafts of
expanded polytetrafluoroethylene [wa]s 100 percent from 4.5 to
11 months following operation." Matsumoto at 519. Further,
Matsumoto also made "microscopic findings [that] showed a
well-formed fibroplasia in the porous layer and a thin,
well-attached neointima on the inner surface of expanded
polytetrafluoroethylene." <i><cite>Id</cite>.</i>

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A "single prior art reference must expressly or inherently
disclose each claim limitation to anticipate a claim.
Additionally, the reference must enable one of ordinary skill
in the art to make the invention without undue
experimentation." <i>Orion</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1D87O8003?jcsearch=605%20f%203d%20967&amp;summary=yes#jcite">605 F.3d at 975</a> (internal
quotation marks and citations omitted). Further, anticipation
must be proved by clear and convincing evidence. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1D87O8003?jcsearch=605%20F.3d%20967&amp;summary=yes#jcite">Id</a>.</i>
Bard presented substantial evidence to support the jury's
verdict of no anticipation by Matsumoto.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442095" href="#headnote_pq2-dec_442095">[2]</a> Regarding whether Matsumoto is enabled, Dr. James Anderson,
Bard's technical expert, testified that Matsumoto did "not
[provide] enough information," including the "characteristics
of the graft material," for a doctor to recreate a working
vascular graft. J.A. 12063-64. This testimony was in addition
to that of Detton, who stated that Matsumoto "wouldn't have
been enough for me to even do much with." J.A. 10960.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Bard also presented evidence that others were unable to
replicate Matsumoto's <span CLASS="page_no" data-cite="670 f 3d 1185" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1185" data-primary-citation="670 F.3d 1171">[*1185]</span> work. Mendenhall testified that the
reaction to Matsumoto was that it was "[k]ind of a fluke,
really" and that "[n]obody was very able to reproduce that."
J.A. 49746. A Gore document titled "Flagstaff Visit: 22:10:73,
Dan Detton" also stated that <span CLASS="page_no" data-cite="2012 bl 32360 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> Matsumoto "claims 100% success on
femoral arteries in dogs: but we do not know what tubes we[re]
used. So we start again." J.A. 102576-77. In addition to this
evidence from Gore's own employees, other experts in the field
also failed to reproduce grafts like Matsumoto's. On December
7, 1973, Dr. Glenn Kelly wrote to Matsumoto and stated that
using "presumably identical material," he was unable to create
grafts that remained unobstructed and did not know how to
resolve the "apparent conflict in our results." J.A. 35044.
Additionally, on February 14, 1975, Dr. Ben Eiseman wrote Dr.
Kensuke Esato in Japan and stated that while Matsumoto
"detailed continued patency of

vessels of 4-5 mm diameter over prolonged periods,"
"neither [h]e nor others in the U.S. [we]re having such good
luck." J.A. 41829. Finally, Dr. Charles Campbell declared that
"[e]fforts in this country to duplicate the results of
Matsumoto have met with failure." J.A. 46193. Thus, Bard
presented substantial evidence for the jury to find that
Matsumoto does not enable a person of ordinary skill in the art
to make the invention without undue experimentation and cannot
be used as anticipatory prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442096" href="#headnote_pq2-dec_442096">[3]</a> Even if Matsumoto were a proper prior art reference, there is
substantial evidence that Matsumoto does not anticipate the
claimed invention. The asserted claims require specific
"average distance[s] between nodes." `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, col.12
ll.4-5, 24, 33, 38. Dr. Jock Wheeler, Gore's own technical
expert, testified that Matsumoto, however, did not refer to
internodal distance, which was "really not mentioned in th[e]
article." J.A. 12064. Although he also stated that the
internodal distance could be "readily calculated from figure 4"
of Matsumoto, J.A. 11247, Goldfarb testified that "there was a
fair amount of inconsistency . . . along each graft" so the
portion of the graft surface depicted in figure 4 was not
representative of the entire graft. J.A. 9371.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the Interference, Cooper himself argued that "[o]ne is left
to speculate as to whether this small portion of the Matsumoto
graft is representative of the fibril length throughout the
entire graft." J.A. 41926. Further, this court noted that
Harold Green, "the individual responsible for manufacturing
expanded PTFE tubing for Gore in 1972-73," testified that there
was "difficulty controlling the uniformity of the PTFE
material" and that "fibril lengths vary along each tube."
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1329</a>. The court also noted that
Goldfarb testified that "fibril

length varied tremendously . . . within the same graft."
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id</a>.</i> (internal quotation omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Matsumoto was already before the PTO during
prosecution of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, <span CLASS="page_no" data-cite="101 uspq 2d 1651" data-cite-type="ReporterOfDecisions" data-cite-pageno="1651" data-primary-citation="101 U.S.P.Q.2d 1641">[**1651]</span> and the PTO did not find that
Matsumoto anticipated the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>. <i>See Am. Hoist</i>
<i>&amp; Derrick Co. v. Sowa &amp; Sons, Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABMGJ?jcsearch=725%20f%202d%201350&amp;summary=yes#jcite">725 F.2d 1350</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABMGJ?jcsearch=725%20f%202d%201350&amp;summary=yes#jcite">1359</a>
(Fed. Cir. 1984), <i>abrogated on other grounds by Therasense,</i>
<i>Inc. v. Becton, Dickinson &amp; Co.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">649 F.3d 1276</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">1288-90</a> (Fed. Cir. 2011) (en banc) (stating that when "no prior
art other than that which was considered by the PTO examiner is
relied on by the attacker, he has the added burden of
overcoming the deference that is due to a qualified government
agency presumed to have properly done its job . . . to issue
only valid patents").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has recently <span CLASS="page_no" data-cite="2012 bl 32360 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> held that invalidity needs to
be proved by clear and convincing evidence. <i>Microsoft Corp.</i>
<i>v. i4i Ltd. P'ship</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S. Ct. 2238</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a> (<span CLASS="page_no" data-cite="670 f 3d 1186" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1186" data-primary-citation="670 F.3d 1171">[*1186]</span> 2011). Based on
this record, a reasonable jury could find that Gore failed to
show by clear and convincing evidence that Matsumoto
anticipated the claimed invention. Accordingly, the district
court did not err in denying Gore's motion for judgment as a
matter of law on anticipation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   C.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  When reviewing the denial of a motion for judgment as a matter
of law, "this court reviews a jury's conclusions on
obviousness, a question of law, without deference, and the
underlying findings of fact, whether explicit or implicit
within the verdict, for substantial evidence."
<i>Muni-auction, Inc. v. Thomson Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X197TO0003?jcsearch=532%20f%203d%201318&amp;summary=yes#jcite">532 F.3d 1318</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X197TO0003?jcsearch=532%20f%203d%201318&amp;summary=yes#jcite">1324</a> (Fed. Cir. 2008) (internal quotations and citations
omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury found the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> valid under <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>
because the subject matter of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> would

not have been obvious to a person of ordinary skill in the
art in light of Volder alone for claims 20 to 24 and 27, or
Volder and Matsumoto in combination for claims 20 to 27.
<i>Verdict Form</i>, at 17. The district court denied Gore's
motion for judgment as a matter of law on obviousness.
<i>Obviousness II</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*7&amp;summary=yes#jcite">at *7</a>; <i>Obviousness</i>
<i>I</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">2008 BL 158898</a>], 2008 WL 2954187, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*6&amp;summary=yes#jcite">at *6</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Volder discusses how "grafts of Gore-Tex porous
polytetrafluoroethylene (G-PTFE) were evaluated" and that
"G-PTFE is a material with extremely promising characteristics"
for A-V shunts. Volder at 38. Volder found that "[s]hunts of
G-PTFE have as favorable characteristics that . . . are readily
available" because "the material withstands puncturing, and
there is neointima healing with extensive ingrowth of
fibroblasts and capillaries." <i></i><cite>Id. at 39</cite>. Additionally,
while "the tissue infiltration is not complete in certain
areas," Volder "believed that by increasing the average pore
size of the material, at the moment 5&frac14;, it will be possible
to accelerate the process of tissue infiltration and
development of capillaries," which would "result in a faster
healing and more durable neointima." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A claim is obvious when "the differences between the subject
matter sought to be patented and the prior art are such that
the subject matter as a whole would have been obvious at the
time the invention was made to a person having ordinary skill
in the art to which said subject matter pertains."
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. To determine whether a patent is obvious, a district
court must base its determination on factual inquiries
involving: (1) the scope and content of the prior art, (2)
differences between the prior art and the claims, (3) the level
of ordinary skill in the pertinent art, and (4) secondary
considerations, such as commercial success, satisfaction of a
long-felt need, and

failure of others. <i>Graham v. John Deere Co. of Kansas</i>
<i>City</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17</a> (1966).<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442097" href="#headnote_pq2-dec_442097">[4]</a> The asserted claims require specific "average distance[s]
between nodes." `<span CLASS="page_no" data-cite="670 f 3d 1187" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1187" data-primary-citation="670 F.3d 1171">[*1187]</span> <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, col.12 ll.4-5, 24, 33, 38. In
light of Volder alone, the district court found that the
following evidence at trial supported the legal conclusion that
claims 20 to 24 and 27 are not obvious:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) Volder was "repeatedly considered by the PTO
  before, during, and after Gore's interference"
  proceeding, in which Gore itself consistently
  distinguished Volder from Goldfarb's invention;
<span CLASS="page_no" data-cite="2012 bl 32360 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (2) Dr. Volder, the author himself, stated under oath
  in an unrebutted affidavit that he thought "that the
  prosthetic vascular structure conceived and developed
  by [Goldfarb] . . . was by no means obvious to those
  actively conducting research on expanded PTFE
<span CLASS="page_no" data-cite="101 uspq 2d 1652" data-cite-type="ReporterOfDecisions" data-cite-pageno="1652" data-primary-citation="101 U.S.P.Q.2d 1641">[**1652]</span> 
  vascular structures during 1972 and 1973";
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (3) researchers were unable to invent a successful
  graft even after Volder and Matsumoto were published,
  and Cooper testified in 1975 that he was "compelled to
  steal Dr. Goldfarb's histology slides" to determine
  why others were not successful;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (4) Goldfarb testified that neither Volder nor
  Matsumoto taught his invention, and Anderson testified
  that he would not have been able to create a working
  graft based on Volder and Matsumoto; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (5) "pore size" and "internodal distance" are not
  synonymous based on several pieces of record evidence,
  including Wilbert L. Gore's, Gore's founder,
  declaration that "`[p]ore size' is not synonymous with
  `fibril length'" in Volder and Cooper and Goldfarb's
  agreement "that pore size bears no relationship to
  fibril length" in the Interference.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Obviousness II</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*4-5&amp;summary=yes#jcite">at *4-5</a> (some internal
quotation marks and citations omitted); <i>see also</i>
<i>Obviousness I</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">2008 BL 158898</a>], 2008 WL 2954187, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*5&amp;summary=yes#jcite">at *5</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In light of Volder and Matsumoto in combination, the court also
found, in addition to its above findings on Volder alone, that
the following evidence at trial supported the legal conclusion
that claims 20 to 27 are not obvious:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) like Volder, Matsumoto was "repeatedly considered
  by the PTO during the

  pendency of the Goldfarb application" and was found
  not to invalidate the claimed invention;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (2) other doctors, including ones working for Gore
  itself, were unable to solve the problems with graft
  development after both Volder and Matsumoto were
  published, and Cooper himself could not determine why
  other researchers were failing;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (3) "other researchers could not determine the
  structure disclosed in" Matsumoto or use Matsumoto "to
  create a working vascular graft";
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (4) Goldfarb's testimony that "Volder and Matsumoto .
  . . did not teach his invention," and Detton's
  testimony that "Gore researchers had no idea what type
  of ePTFE vascular graft Matsumoto used"; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (5) "Gore's own damaging admissions" that Matsumoto
  "failed to disclose the key parameter of internodal
  distance."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">Id</a>.</i> <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*5&amp;summary=yes#jcite">at *5</a>-6 (internal quotation marks and citations
omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's exhaustive findings, summarily recited
above, delineate the substantial evidence presented at trial to
the jury about the scope and contents of Volder and Matsumoto,
their differences from the claimed invention, and the objective
indicia of nonobviousness. <i>See Obviousness II</i>,
[<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*4-6&amp;summary=yes#jcite">at *4-6</a>; <i>Obviousness I</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">2008 BL 158898</a>], 2008 WL 2954187, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*5&amp;summary=yes#jcite">at
*5</a>. Neither Volder nor Matsumoto disclosed <span CLASS="page_no" data-cite="670 f 3d 1188" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1188" data-primary-citation="670 F.3d 1171">[*1188]</span> the importance of
the internodal distance. Thus, the jury's verdict that claims
20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> are not invalid as obvious in light
of

Volder alone, or Volder and Matsumoto in combination, is
clearly supported. The district court did not err in denying
Gore's motion for judgment as a matter of law on obviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court determined that for the same reasons that it
found Volder and Matsumoto in combination would <span CLASS="page_no" data-cite="2012 bl 32360 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> not render the
`<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> obvious, there was also no basis for finding claims
20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> obvious in light of Matsumoto
alone.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a> <i>Obviousness II</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*7&amp;summary=yes#jcite">at *7</a>. We
agree. For the reasons stated above regarding the
nonobviousness of claims 20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> in light
of Volder and Matsumoto in combination and Matsumoto's failure
to anticipate claims 20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, the district
court did not err in denying Gore's motion for judgment as a
matter of law that Matsumoto alone renders claims 20 to 27 of
the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   D.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The issue of whether "a patent is invalid for failure to meet
the written description requirement of <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>,
&para; 1 is a question of fact, and we review a jury's
determinations of facts relating to compliance with the written
description requirement for substantial evidence." <i>Ariad</i>
<i>Pharm., Inc. v. Eli Lilly &amp; Co.<span CLASS="page_no" data-cite="101 uspq 2d 1653" data-cite-type="ReporterOfDecisions" data-cite-pageno="1653" data-primary-citation="101 U.S.P.Q.2d 1641">[**1653]</span> </i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d 1336</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">1355</a>
(Fed. Cir. 2010) (en banc) (internal quotation marks and
citations omitted). The written description issue in this

case is whether the written description of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>
supports the claims that are not limited to a prosthesis with a
wall thickness of 0.2 to 0.8 mm, namely claims 20 to 24 and 27.
The jury determined that claims 20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>
were not invalid for lack of adequate written description.
<i>Verdict Form</i>, at 19. The district court found that
substantial evidence demonstrated that wall thickness is not an
essential element of Goldfarb's invention and, thus, denied
Gore's motion for judgment as a matter of law for lack of
written description. <i>Post-Trial I</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d at 1091</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patent's written description must "`clearly allow persons of
ordinary skill in the art to recognize that [the inventor]
invented what is claimed.'" <i>Ariad</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d at 1351</a>
(quoting <i>Vas-Cath Inc. v. Mahurkar</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X30HGT?jcsearch=935%20f%202d%201555&amp;summary=yes#jcite">935 F.2d 1555</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X30HGT?jcsearch=935%20f%202d%201555&amp;summary=yes#jcite">1563</a> (Fed. Cir. 1991)). The test for sufficiency of written
description is "whether the disclosure of the application
relied upon reasonably conveys to those skilled in the art that
the inventor had possession of the claimed subject matter as of
the filing date." <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id</a>.</i> (citations omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442098" href="#headnote_pq2-dec_442098">[5]</a> The `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> states that "the average internodal distance,
as measured along the axis of expansion 12, <i>must</i> fall
within a relatively narrow range of values, viz., between
approximately 6 and 80 microns." Col.5 ll.31-34 (emphasis
added). Thus, a specific average internodal distance is a
requirement of the claimed invention. <i>See <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">id</a>.</i>
Alternatively, the written description also states that "[w]all
thickness is another <i>factor</i> affecting the
establish-ment and maintenance of a viable neointima in
grafts." <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">Id</a>.</i> col.6 ll.40-42 (emphasis added). Thus,
although "[g]rafts embodying <span CLASS="page_no" data-cite="670 f 3d 1189" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1189" data-primary-citation="670 F.3d 1171">[*1189]</span> the present invention, having wall
thicknesses in the range between 0.2 and 0.8 millimeters . . .
have exhibited excellent mechanical properties" and "[g]rafts
falling outside these ranges have been found to be marginal or
clinically unacceptable," the language of

the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> does not mandate a wall thickness within
the stated range for the claimed invention. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">Id</a>.</i> col.7
ll.9-13, 15-17; <i>see Martek Biosciences Corp. v. Nutrinova,</i>
<i>Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BLN4S003?jcsearch=579%20f%203d%201363&amp;summary=yes#jcite">579 F.3d 1363</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BLN4S003?jcsearch=579%20f%203d%201363&amp;summary=yes#jcite">1371</a> (Fed. Cir. 2009) ("[A] patent
claim is not necessarily invalid for lack of written
description just because it is broader than the specific
examples disclosed.") (citations omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, in the Interference, the PTO itself <span CLASS="page_no" data-cite="2012 bl 32360 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> proposed a
count that did not include a wall thickness limitation. <i>See</i>
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1326</a>. Even though Goldfarb testified
that a graft outside the range of 0.2 to 0.8 mm was
"technically harder to handle," he did "not say[] it wouldn't
work." J.A. 32117. Further, although Goldfarb moved to amend
the count to include a range for wall thickness, the PTO denied
the motion because "there is evidence that fibril length is
<i>the</i> critical variable, and in terms of an
interference, the broadest possible patentable claim must be
used as the count" and an amended count with a wall thickness
limitation would be "narrower than the present count." J.A.
41463. Cooper himself responded that "[o]nce it is known that
fibril length is the key to successful tissue growth, however,
optimizing the other structural features of the graft is, and
was, a matter of routine experimentation" and that "[t]he
present count . . . is <i>supported by each party's</i>
<i>application</i> [and] broadly <i>covers the real</i>
<i>invention.</i>" J.A. 25672-73 (emphases added); <i>see</i>
<i>also</i> J.A. 41462 ("Cooper argues . . . vigorously that only
fibril length is critical to the operability of the claimed
device.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, at trial, Goldfarb testified that his invention did
not require a specific wall thickness because "wall thicknesses
were really dependent on the application of the graft and not
one wall thickness for all . . . implantations" was
appropriate. J.A. 9400-01.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, substantial evidence supports the jury's finding
that claims 20 to 24 and 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> are not invalid
for lack of written description, and the district court did not
err in denying Gore's motion for judgment as a matter of law on
the issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   E.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Determining whether or not infringement is willful is a
question of fact that must be established by clear and
convincing evidence and is reviewed for substantial evidence.
<i>Comark Commc'ns, Inc. v. Harris Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XACBUP?jcsearch=156%20f%203d%201182&amp;summary=yes#jcite">156 F.3d 1182</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XACBUP?jcsearch=156%20f%203d%201182&amp;summary=yes#jcite">1190</a> (Fed. Cir. 1998). The jury found that Gore's infringement
of claims 20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> was willful, despite a
November 2002 opinion of counsel that the claims of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135
patent</a> were invalid. <i>Verdict Form</i>, at 20. The district
court found that there was "sufficient evidence for the jury to
have found willful infringement by clear and convincing
evidence." <i>Post-Trial I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d at 1089</a>. The
evidence included an extensive litigation history before the
PTO where Goldfarb was the sole inventor and Gore was the
losing party, and also included Gore's reliance on the same
references that were before the PTO, which the PTO found did
not invalidate the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, to support its invalidity
defenses. <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20F.%20Supp.%202d%201083&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To establish willful infringement, "a patentee must show by
clear and convincing evidence that the infringer acted despite
an objectively <span CLASS="page_no" data-cite="101 uspq 2d 1654" data-cite-type="ReporterOfDecisions" data-cite-pageno="1654" data-primary-citation="101 U.S.P.Q.2d 1641">[**1654]</span> high likelihood that its actions constituted
infringement of a valid patent." <i>In re Seagate Tech.,</i>
<i>LLC<span CLASS="page_no" data-cite="670 f 3d 1190" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1190" data-primary-citation="670 F.3d 1171">[*1190]</span> </i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17H3LC003?jcsearch=497%20f%203d%201360&amp;summary=yes#jcite">497 F.3d 1360</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17H3LC003?jcsearch=497%20f%203d%201360&amp;summary=yes#jcite">1371</a> (Fed. Cir. 2007) (en banc). For a
finding of willfulness, once the "threshold objective standard
is satisfied, the patentee must also demonstrate that this
objectively-defined risk . . . was either known or so obvious
that it should have been known to the accused infringer."
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17H3LC003?jcsearch=497%20F.3d%201360&amp;summary=yes#jcite">Id</a>.</i> Drawing inferences,

especially for "an intent-implicating question such as
willfulness, is peculiarly <span CLASS="page_no" data-cite="2012 bl 32360 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> within the province of the fact
finder that observed the witnesses." <i>Rolls-Royce Ltd. v.</i>
<i>GTE Valeron Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABRVO?jcsearch=800%20f%202d%201101&amp;summary=yes#jcite">800 F.2d 1101</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABRVO?jcsearch=800%20f%202d%201101&amp;summary=yes#jcite">1110</a> (Fed. Cir. 1986).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442099" href="#headnote_pq2-dec_442099">[6]</a> Bard presented substantial evidence to satisfy both prongs of
the <i>Seagate</i> standard and support the jury's finding
that Gore's infringement was willful. The jury heard evidence
of the eighteen-year Interference, in which Goldfarb was
awarded priority of invention. <i>Post-Trial I</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA4003?jcsearch=586%20f%20supp%202d%201083&amp;summary=yes#jcite">586 F. Supp. 2d at 1089</a>; <i>see Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d 1378</a>;
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d 1321</a>. Based on the Interference,
Gore was aware of both the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/1?citation=usp%206436135&amp;summary=yes#jcite">135 patent</a>'s existence and
Goldfarb's research activities at AHI. In addition, Gore
relied on Matsumoto and Volder to support its invalidity
defenses, even though those references were previously
considered and rejected as not invalidating by the PTO.
<i>See</i> `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> at [56]; <i>Am. Hoist</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABMGJ?jcsearch=725%20f%202d%201350&amp;summary=yes#jcite">725 F.2d at 1359</a>. Further, for example, the district court found that
"Gore ha[d] no valid evidentiary basis for meritoriously
arguing that Claims 20 through 27 of the Goldfarb patent
[we]re, by clear and convincing evidence, obvious" in light of
Matsumoto and Volder, which was "not a close call."
<i>Obviousness II</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=2009%20BL%2067869&amp;summary=yes#jcite">2009 BL 67869</a>], 2009 WL 886515, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ARSGQ003?jcsearch=at%20*7&amp;summary=yes#jcite">at *7</a>. Based on this
evidence alone, it would have been reasonable for the jury to
find that Gore manufactured and sold grafts despite an
objectively high likelihood the grafts infringed the valid `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135
patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, "an infringer's reliance on favorable advice of
counsel . . . is not dispositive of the willfulness inquiry."
<i>Seagate</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17H3LC003?jcsearch=497%20f%203d%201360&amp;summary=yes#jcite">497 F.3d at 1369</a>. In cases "where willful
infringement is found despite the presence of an opinion of
counsel," the "opinion of counsel was either ignored or found
to be incompetent." <i>Read Corp. v. Portec, Inc.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54757?jcsearch=970%20f%202d%20816&amp;summary=yes#jcite">970 F.2d 816</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54757?jcsearch=970%20f%202d%20816&amp;summary=yes#jcite">829</a> (Fed. Cir. 1992), <i>superseded on other grounds</i>
<i>as recognized by Hoechst Celanese Corp. v.</i>

<i>BP Chems. Ltd.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X39VL8?jcsearch=78%20f%203d%201575&amp;summary=yes#jcite">78 F.3d 1575</a> (Fed. Cir. 1996). As
the district court determined, Bard presented substantial
evidence that Gore's opinion of counsel was not based on an
objective perspective. <i>Damages</i>, <cite>slip op. at 9-11</cite>. In
addition to the opinion's reliance on Matsumoto and Volder,
which were already rejected by the PTO, the bases of alleged
invalidity asserted in the opinion were "directly contrary to
the validity arguments [Gore] presented to the PTO when
attempting to patent Dr. Goldfarb's invention."
<i>Damages</i>, <cite>slip op. at 9</cite>. With the same law firm
representing Gore both before and after the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> was
issued, the district court viewed the objectivity of the
opinion as questionable. <i></i><cite>Id. at 10</cite>. The district court
also found that the opinion was not "premised on the best
evidence available" because it excluded certain available
evidence that was relevant to Gore's invalidity defenses.
<i><cite>Id</cite>.</i> Thus, there was also substantial evidence
presented to the jury that supports the finding that Gore knew
or should have known of the objectively high likelihood that
its grafts infringed the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Gore's presentation of "several defenses at trial . . . does
not mean the jury's willfulness finding lacks a sufficient
evidentiary basis. . . . [T]he jury was free to decide for
itself whether [Gore] reasonably believed there were any
substantial defenses to a claim of infringement." <i>i4i Ltd.</i>
<i>P'ship v. Microsoft Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CQR6E003?jcsearch=598%20f%203d%20831&amp;summary=yes#jcite">598 F.3d 831</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CQR6E003?jcsearch=598%20f%203d%20831&amp;summary=yes#jcite">860</a> (Fed. Cir.
2010), <i>aff'd</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S. Ct. 2238</a> (<span CLASS="page_no" data-cite="670 f 3d 1191" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1191" data-primary-citation="670 F.3d 1171">[*1191]</span> 2011) (citations
omitted). Accordingly, substantial evidence supports the jury's
finding that Gore willfully <span CLASS="page_no" data-cite="2012 bl 32360 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> infringed the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>, and the
district court did not err in denying Gore's motion for
judgment as a matter of law on willfulness.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   F.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury concluded that Bard was entitled to damages for Gore's
infringement of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a>: lost profits in the amount of
$102,081,578.82, reasonable royalties in the amount of
$83,508,292.20, and a reasonable royalty rate of 10%.
<i>Verdict Form</i>, at 22-23. In exercising its discretion,
the district court awarded Bard double enhanced damages of
$371,179,742.04 and attorneys' fees and costs of $19 million.
<i>Damages</i>, slip op. at 23.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Section <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEJ054003?jcsearch=35%20U.S.C.%20%20284&amp;summary=yes#jcite">284</a> of Title 35 of the United States Code al-lows a
court to "increase the damages up to three times the amount
found or assessed." This court has held that "an award of
enhanced damages requires a showing of willful infringement."
<i>Seagate</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17H3LC003?jcsearch=497%20f%203d%201360&amp;summary=yes#jcite">497 F.3d at 1368</a>. However, "the decision to
grant or deny enhanced damages remains firmly within the scope
of the district court's reasoned discretion, informed by the
totality of the circumstances." <i>Odetics, Inc. v. Storage</i>
<i>Tech. Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X36BBD?jcsearch=185%20f%203d%201259&amp;summary=yes#jcite">185 F.3d 1259</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X36BBD?jcsearch=185%20f%203d%201259&amp;summary=yes#jcite">1274</a> (Fed. Cir. 1999).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442100" href="#headnote_pq2-dec_442100">[7]</a> The district court did not abuse its discretion in awarding
enhanced damages. In addition <span CLASS="page_no" data-cite="101 uspq 2d 1655" data-cite-type="ReporterOfDecisions" data-cite-pageno="1655" data-primary-citation="101 U.S.P.Q.2d 1641">[**1655]</span> to the jury's finding of
willfulness that is supported by substantial evidence, the
court conducted a detailed and exhaustive review of all nine
<i>Read</i> factors to ascertain whether Gore acted in bad
faith to merit an increase of the jury's damages award.
<i>Damages</i>, slip op. at 4-19. The <i>Read</i> factors
for determining whether an infringer has acted in bad faith
include:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) whether the infringer deliberately copied the
  ideas or design of another; (2) whether the infringer,
  when he knew of the other's patent protection,
  investigated the scope of the patent and formed a
  good-faith belief that it was invalid or that it was
  not infringed; (3) the infringer's behavior

  as a party to the litigation; (4) defendant's size and
  financial condition; (5) closeness of the case; (6)
  duration of defendant's misconduct; (7) remedial
  action by the defendant; (8) defendant's motivation
  for harm; and (9) whether defendant attempted to
  conceal its misconduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Liquid Dynamics Corp. v. Vaughan Co.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1547FA003?jcsearch=449%20f%203d%201209&amp;summary=yes#jcite">449 F.3d 1209</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1547FA003?jcsearch=449%20f%203d%201209&amp;summary=yes#jcite">1225</a> (Fed. Cir. 2006) (citing <i>Read</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54757?jcsearch=970%20f%202d%20816&amp;summary=yes#jcite">970 F.2d at 826-27</a>). The court found that all of the factors, except as to
whether Gore attempted to conceal its misconduct, weighed in
favor of enhanced damages. Three of those eight favorable
factors, however, were only slightly in favor of enhancement:
namely, the good faith belief of invalidity or
non-infringement, behavior as a party to the litigation, and
closeness of the case. <i>Damages</i>, <cite>slip op. at 19-20</cite>.
Thus, the court exercised its discretion by only doubling the
jury's damages award, and not tripling as it had the authority
to do. <i></i><cite>Id. at 20</cite>. Based on the evidence, the district
court did not abuse its discretion in awarding enhanced damages
to Bard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442101" href="#headnote_pq2-dec_442101">[8]</a> Section <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEJ056003?jcsearch=35%20U.S.C.%20%20285&amp;summary=yes#jcite">285</a> of Title 35 of the United States Code states that a
"court in exceptional cases may award reasonable attorney fees
to the prevailing party." Whether a case is exceptional and,
thus, eligible for an award of attorneys' fees requires the
district court to first, make a factual determination of
whether a case is exceptional and second, exercise its
discretion to determine whether attorneys' <span CLASS="page_no" data-cite="2012 bl 32360 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> fees are
appropriate. <i>Cybor</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">138 F.3d at 1460</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span CLASS="page_no" data-cite="670 f 3d 1192" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1192" data-primary-citation="670 F.3d 1171">[*1192]</span> The district court also found that there was sufficient basis
for deeming this case exceptional based on the jury's verdict
of willfulness, the evidence supporting willfulness, and the
extensive litigation history between the parties that Gore
repeatedly lost yet continued to infringe.

<i>Damages</i>, <cite>slip op. at 21-22</cite>. The court also
determined that Gore argued contradictory positions on
infringement throughout the litigation and relied on testimony
that was not credible. <i></i><cite>Id. at 22-23</cite>. Thus, the court
concluded that this case was exceptional, justifying the
exercise of its discretion in awarding of attorneys' fees and
costs.<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> Based on the record, the district court did not
abuse its discretion in awarding Bard attorneys' fees and
costs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court denied Bard's request for a permanent
injunction finding that it was in the public interest to allow
competition in the medical device arena, but in lieu thereof
granted Bard an ongoing royalty to compensate for Gore's future
infringement. <i>Injunction</i>, <cite>2009 WL 920300</cite>, <cite>at *4-10</cite>;
<i>see eBay Inc. v. MercExchange, L.L.C.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X151TO4003?jcsearch=547%20us%20388&amp;summary=yes#jcite">547 U.S. 388</a>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X151TO4003?jcsearch=547%20us%20388&amp;summary=yes#jcite">391</a> (2006) (permitting the denial of a permanent injunction if
the public interest would be disserved). The court set a 12.5%
to 20% royalty rate on Gore's grafts depending on the different
types of graft. <i>License</i>, slip op. at 15-16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The award of an ongoing royalty instead of a permanent
injunction to compensate for future infringement is appropriate
in some cases. <i>Paice</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20f%203d%201293&amp;summary=yes#jcite">504 F.3d at 1314</a>; <i>see also</i>
<i>Shatterproof</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20F.2d%20at%20628&amp;summary=yes#jcite">758 F.2d at 628</a> (upholding a court-ordered
royalty based on sales as a remedy for continuing operations).
Because of the public interest as the court here determined,
"the district court may wish to allow the parties to negotiate
a license amongst themselves regarding future use of a patented
invention before imposing an ongoing royalty." <i>Paice</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20f%203d%201293&amp;summary=yes#jcite">504 F.3d at 1315</a>. But if the parties cannot reach agreement,
"the district court could step in to assess a reasonable
royalty in light of the ongoing

infringement." <i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20F.3d%201293&amp;summary=yes#jcite">Id</a>.</i> For this court to determine
whether the district court abused its discretion in setting the
ongoing royalty rate, the district court must explain the
reasoning in establishing the appropriate royalty rate.
<i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20F.3d%201293&amp;summary=yes#jcite">Id</a>.</i> (citing <i>Hensley v. Eckerhart</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CAFH?jcsearch=461%20us%20424&amp;summary=yes#jcite">461 U.S. 424</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CAFH?jcsearch=461%20us%20424&amp;summary=yes#jcite">437</a> (1983) ("It [is] important . . . for the district
court to provide a concise but clear explanation of its reasons
for the fee award.")).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_442102" href="#headnote_pq2-dec_442102">[9]</a> Here, Bard proposed a royalty rate of 35% for Gore's surgical
graft products and 20% for Gore's stent graft products, while
Gore proposed a royalty rate of 5.25% for all of its infringing
products. <i>License</i>, slip op. at 4. The district court
explained its reasons for establishing the various royalty
rates at "20% on surgical grafts, 15% on stent-grafts, 12.5% on
the VIABAHN&reg; stent-graft, and 15% on the PROPATEN&reg;
surgical graft against" Gore. <span CLASS="page_no" data-cite="101 uspq 2d 1656" data-cite-type="ReporterOfDecisions" data-cite-pageno="1656" data-primary-citation="101 U.S.P.Q.2d 1641">[**1656]</span> <i></i><cite>Id. at 15-16</cite>. The court
reasoned that a different royalty rate was warranted between
Gore's surgical and stent graft products because for surgical
graft products, Gore competes directly with Bard in the more
established market, while for stent graft products, a more
recently developed market, Bard does not presently directly
compete with Gore. <i></i><cite>Id. at 12</cite>. Thus, the court
concluded <span CLASS="page_no" data-cite="2012 bl 32360 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> that "a free-market license between Bard and Gore
would separate the royalty rates on the two sets of products to
account for those differences." <i><cite>Id</cite>.</i> Thus, taking
economic market forces into account is a reasonable and valid
assumption by the district court.
<span CLASS="page_no" data-cite="670 f 3d 1193" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1193" data-primary-citation="670 F.3d 1171">[*1193]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, the district court determined that the ongoing royalty on
all of Gore's products "should be higher than the 10%
reasonable royalty rate" set by the jury. <i><cite>Id</cite>.</i> The
court considered the parties' changed legal post-verdict
status: namely that the jury found the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> enforceable
and not invalid and Gore had willfully infringed; the court
deemed this case exceptional so that Bard was

awarded enhanced damages and attorneys' fees and costs; and
Gore voluntarily chose to continue its post-verdict
infringement unabated. <i></i><cite>Id. at 13</cite>; <i>see Amado v.</i>
<i>Microsoft Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X18IN06003?jcsearch=517%20f%203d%201353&amp;summary=yes#jcite">517 F.3d 1353</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X18IN06003?jcsearch=517%20f%203d%201353&amp;summary=yes#jcite">1361-62</a> (Fed. Cir. 2008)
("Prior to judgment, liability for infringement, as well as the
validity of the patent, is uncertain, and damages are
determined in the context of that uncertainty. Once a judgment
of validity and infringement has been entered, however, the
[damages] calculus is markedly different because different
economic factors are involved." (citation omitted)). The court
also considered other economic factors, including that Bard and
Gore compete directly with respect to surgical grafts, Gore
profits highly from its infringing products, Gore potentially
faces stiffer losses that include a permanent injunction if
Bard prevails in a second lawsuit, and Bard seeks adequate
compensation and lacks incentive to accept a below-market deal.
<i></i><cite>Id. at 13</cite>. Finally, the court reasoned that the value
Gore added to its VIABAHN&reg; and PROPATEN&reg; grafts that
are bonded with heparin warranted lower royalty rates on those
products. <i></i><cite>Id. at 13</cite>. Based on the district court's
reasoning, the court did not abuse its discretion in setting a
12.5% to 20% royalty rate for the ongoing royalty on Gore's
infringing grafts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the district court's award of enhanced damages,
attorneys' fees and costs, and an ongoing royalty as described
in thorough and well-reasoned orders was not an abuse of
discretion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, we affirm the judgment that the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135
patent</a> is valid and willfully infringed because the jury's
verdict is supported by substantial evidence. We also conclude
that the district court did not abuse its discretion in
awarding enhanced damages,

attorneys' fees and costs, and an ongoing royalty. We
commend the district court for its well-reasoned and
wellgrounded opinions and its extensive and thoughtful analysis
of the case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The majority affirms on the record presented after two
previous appeals to this court and facts as found by the United
States Patent and Trademark Office and a jury. Contrary to the
dissent, we are not free to ignore the long history of this
case and these prior determinations. We cannot revisit the
facts anew, nor meander through the record and select facts
like our favorite jelly beans, nor characterize the facts as
the Bard would in a Shakespearean tragedy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> As in <i>Paice LLC v. Toyota Motor Corp.</i>,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We use the term ongoing royalty to distinguish this
  equitable remedy from a compulsory license. The term
  "compulsory license" implies that anyone who meets
  certain criteria has congressional authority to use
  that which is licensed. By contrast, the
  ongoing-royalty order at issue here is limited to one
  particular . . . defendant[]; there is no implied
  authority in the court's order for any other [graft]
  manufacturer to follow in [Gore]'s footsteps and use
  the patented invention with the court's imprimatur.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20f%203d%201293&amp;summary=yes#jcite">504 F.3d 1293</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X17QUH8003?jcsearch=504%20f%203d%201293&amp;summary=yes#jcite">1314</a> n. 13 (Fed. Cir. 2007) (citation
omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The jury also found that Dr. Volder, who was not a party
to this litigation and the author of a prior art article, was
not the sole inventor and that Dr. Volder and Goldfarb were not
joint inventors. <i>Verdict Form</i>, at 18. Gore did not
appeal this finding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The dissent complains that Detton recanted some other
earlier testimony during trial, Dissent at 11-13, but the jury
was not required to believe his changed testimony. It could and
did believe his original testimony. And "[i]n reviewing a jury
verdict, the court must draw all reasonable inferences in favor
of the verdict, without making credibility determinations and
without reweighing the evidence." <i>Johns Hopkins Univ. v.</i>
<i>Datascope Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19NE7S003?jcsearch=543%20f%203d%201342&amp;summary=yes#jcite">543 F.3d 1342</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19NE7S003?jcsearch=543%20f%203d%201342&amp;summary=yes#jcite">1350</a> (Fed. Cir. 2008)
(Newman, J., dissenting) (citing <i>Reeves v. Sanderson</i>
<i>Plumbing Prods., Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CC3K?jcsearch=503%20us%20133&amp;summary=yes#jcite">503 U.S. 133</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CC3K?jcsearch=503%20us%20133&amp;summary=yes#jcite">150</a> (2000)) ("When
reviewing a jury verdict, it is impermissible for the appellate
court to substitute its own findings based on the evidence that
was before the jury. . . ." (citing <i>Anderson v. Liberty</i>
<i>Lobby, Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CBAN?jcsearch=477%20us%20242&amp;summary=yes#jcite">477 U.S. 242</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5CBAN?jcsearch=477%20us%20242&amp;summary=yes#jcite">255</a> (1986))); <i>see also</i>
<i>Johnson</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50S3R?jcsearch=251%20f%203d%201222&amp;summary=yes#jcite">251 F.3d at 1227</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> This statement is directly contrary to the dissent's
characterization of Goldfarb as nothing more than a scientist
acting at Gore's direction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> We note that despite this substantial evidence, the
dissent insists that Goldfarb "did not invent the effective
graft materials." Dissent at 16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Notably, the dissent cites to <i>Shatterproof</i> for
the proposition that one "may use the services, ideas, and aid
of others in the process of perfecting his invention without
losing his right to a patent," but simultaneously ignores
<i>Shatterproof</i>'s recognition &mdash; on the same page
&mdash; that "to the extent that conflicting viewpoints were
presented [at trial], this was within the province of the
jury." <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20F.2d%20at%20624&amp;summary=yes#jcite">758 F.2d at 624</a> (Newman, J.).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> The dissent also cites to an article by Volder. Dissent
at 5. This reference is dealt with in subsection C of the
Discussion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> In regard to Cooper's notes on Kelly's results, this
court previously found that, "[t]he next page of Cooper's
laboratory notebook is dated May 2, 1973. It refers to Dr.
Kelly's experiments and samples submitted by Dr. Kelly. The
page bears the following notation: `Both [samples] from Dr.
Glenn Kelly U of Colorado. Femoral Vein in Dogs &mdash; Both
Failed.' The page was signed by Cooper on May 2. . . ."
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1325</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> We note that the dissent also complains that counsel for
Bard repeatedly mentioned during trial that Goldfarb came up
with invention. We decline to address this argument because
neither the dissent nor Gore's brief provide a legal reason why
those statements constitute error. Additionally, it should be
noted that counsel for Gore also repeatedly mentioned that
Cooper was the one who first conceived of the invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> Bard argues that Gore waived all theories of obviousness
except that claim 20 was invalid in light of Volder alone
because that was the only Rule 50(a) motion Gore made before
the jury verdict. However, the district court specifically held
that "any renewed JMOL motion Gore chooses to file as to
obviousness shall not be limited to Claim 20 and the Volder
article." <i>Obviousness I</i>, [<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=2008%20BL%20158898&amp;summary=yes#jcite">2008 BL 158898</a>], 2008 WL 2954187, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X19AAA0003?jcsearch=at%20*4&amp;summary=yes#jcite">at *4</a>. This
court is "not disposed to override a district court's
determination of non-waiver." <i>Trading Techs. Int'l, Inc. v.</i>
<i>eSpeed, Inc.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CJOFK003?jcsearch=595%20f%203d%201340&amp;summary=yes#jcite">595 F.3d 1340</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1CJOFK003?jcsearch=595%20f%203d%201340&amp;summary=yes#jcite">1360</a> (Fed. Cir. 2010)
(internal quotation marks omitted). Thus, we will not disturb
the district court's determination that Gore's renewed motions
for judgment as a matter of law on obviousness beyond claim 20
in light of Volder alone were not waived.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> The jury's verdict form did not designate whether claims
20 to 27 of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> were obvious in light of Matsumoto
alone, <i>see Verdict Form</i>, at 17, but it did ask whether
those claims of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> were obvious in light of Volder
and Matsumoto, without specifying whether both references had
to be considered in combination, <i><cite>id</cite>.</i> Based on the
verdict form, the jury could have found that Matsumoto alone
rendered those claims of the `<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X310CC11H8J?jcsearch=usp%206436135&amp;summary=yes#jcite">135 patent</a> invalid as
obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> The parties stipulated that $19 million was a reasonable
amount of attorneys' fees and non-taxable costs in this case.
<i>Damages</i>, slip op. at 21.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  NEWMAN, <i>Circuit Judge</i>, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court today holds that a person who performs the
requested test of a material that is provided to him for
testing for a specified use, can then, when the test is
successful, patent the material he was provided, for the use
for which it was tested. My colleagues hold that Dr.

David Goldfarb, who was provided with Gore-Tex&reg; tubular
material for testing as a vascular graft in dogs, can patent as
his own the Gore-Tex material that Gore employees provided to
him, and assert the exclusive right to the use for which the
material <span CLASS="page_no" data-cite="2012 bl 32360 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> was provided. My colleagues hold that Dr. Goldfarb
then can enforce this patent against the provider of the
Gore-Tex material that he tested. My colleagues on this panel
endorse and defend these errors and improprieties, and now
rule that Gore is the willful infringer of this improperly obtained
patent on Gore's product and use. My colleagues find no blemish
in this history of incorrect law, impropriety, questionable
advocacy, and confessed perjury. I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The saga of the patent in this suit starts in February 1973,
when employees of W.L. <span CLASS="page_no" data-cite="670 f 3d 1194" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1194" data-primary-citation="670 F.3d 1171">[*1194]</span> Gore &amp; Associates, in connection
with an ongoing program led by Gore's Plant Manager Peter
Cooper, invited Dr. Goldfarb at the Arizona Heart Institute to
participate in testing the Gore-Tex expanded
polytetrafluoroethylene (ePTFE) for use as a vascular graft.
Gore-Tex ePTFE had already been successfully tested as vascular
grafts in dogs and sheep, by surgeons at various universities
and hospitals. Peter Cooper and Gore employee Richard
Mendenhall visited Dr. Goldfarb, told him of the material, its
properties, and the results obtained and in progress, and
invited him to participate in the testing program. Dr. Goldfarb
accepted the invitation, and Cooper provided him with several
Gore-Tex tubes with the ePTFE structures that had been found to
be most effective as vascular grafts, in studies by the other
researchers. Dr. Goldfarb then implanted in dog <span CLASS="page_no" data-cite="101 uspq 2d 1657" data-cite-type="ReporterOfDecisions" data-cite-pageno="1657" data-primary-citation="101 U.S.P.Q.2d 1641">[**1657]</span> arteries the
Gore-Tex tubes that Cooper provided, observed that the material
was indeed effective, and in October 1974 filed a patent
application on the effective

Gore-Tex graft materials and this use, naming himself as
the inventor.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Gore had already filed a patent application on the effective
Gore-Tex graft materials, with Peter Cooper as inventor.
Prosecution continued for twenty-eight years, including a
patent "interference" that lasted for eighteen years, with two
appeals to the Federal Circuit. On August 20, 2002 the Patent
and Trademark Office ("PTO") issued a patent to Dr. Goldfarb.
In 2003 Goldfarb and his then-assignee, the C.R. Bard Company,
sued Gore for patent infringement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The record shows Gore's extensive experience with these
Gore-Tex graft materials, experience that preceded Dr.
Goldfarb's entry into Gore's testing program, including various
prior art activities of record in the PTO. Dr. Goldfarb
acknowledged in the interference proceeding that use of
Gore-Tex ePTFE as a mammalian graft had been known as early as
1970 or 1971, when Dr. Ben Eiseman of the University of
Colorado began testing Gore-Tex vascular grafts. <i>Brief for</i>
<i>the Junior Party David Goldfarb</i>, Interference No. 101,100,
PX 116.6818 at 6, in <i>Bard v. Gore</i>, No<cite>. CV
03-0597-PHX-MHM.</cite> Dr. Goldfarb also acknowledged to the PTO that
"[a]t about the same time, Dr. Matsumoto in Tokyo, Japan,
obtained a sample of expanded PTFE tubing and implanted it in
dogs as a small diameter graft," and "Matsumoto reported a 100%
success rate. . . ." <i></i><cite>Id. at 7</cite>. Dr. Matsumoto, of the
Department of Thoracic Surgery of the University of Tokyo,
published several scientific articles on this work,
<i>e.g.</i>, Matsumoto <i>et al.</i>, "Studies <span CLASS="page_no" data-cite="2012 bl 32360 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> of Porous
Polytetrafluoroethylene as a Vascular Prosthesis: Application
to Peripheral Arteries," <i>Artificial Organs</i>, Vol 1,
No. 1, p. 44 (1972). Another Matsumoto publication, in
<i>Surgery</i>, Vol. 74, No. 4, p. 519 (October 1973) states
that "Gore-Tex tubes manufactured by W. L. Gore Associates"
were implanted

in dogs for up to ten months. The <i>Surgery</i>
article states that after the implant period "the internal surface of
the grafts were visualized macroscopically and
microscopically," and includes photomicrographs of the Gore-Tex
tubes showing the fibrous and internodal structure that is
claimed in the Goldfarb patent. Figure 3 of the
<i>Surgery</i> article is a photomicrograph "of an expanded
polytetrafluoroethylene prosthesis removed ten months after
operation. The neointima is very well developed and firmly
adherent to the inner surface"; properties that the jury (and
the PTO) was told were discovered by Dr. Goldfarb. Figure 4 is
a "microscopic picture of an expanded polytetrafluoroethylene
prosthesis removed 4.5 months after operation. Fibroplasis is
well formed through pores"; these are all properties that the
jury and <span CLASS="page_no" data-cite="670 f 3d 1195" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1195" data-primary-citation="670 F.3d 1171">[*1195]</span> the PTO were told were discovered by Dr. Goldfarb.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 1972, well before Dr. Goldfarb was first contacted by the
Gore employees, an internal memorandum written by Cooper
entitled "Who Is Doing What With GORE-TEX Veins and Arteries
and Other Experiments," dated August 15, 1972, reports
experiments conducted by Dr. Jay Volder of the University of
Utah, using Gore-Tex tubes provided by Cooper, for vascular
grafts in sheep:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  4. University of Utah: Dr. Jay Volder &mdash; Jugular
  Vein, Carotid Arteries 5.3 and 9.9 mm. On Dr. Kolff's
  Staff.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  10 sheep each. Arteries are perfect. Some veins
  clotted in a few weeks. When smaller, more porous
  tubes were used as veins, they did not clot but the
  intima "was not well adhered". Do not know if higher
  flow rates or more porous structure was cause of
  better success &mdash; could be both. We will supply
  even more highly expanded 5 mm material,

  .2-.3 gms/cc compared to .53 which he used. He plans
  to write a paper.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
PX 116.17703, <i>Bard v. Gore</i>, No<cite>. CV 03-0597-PHX-MHM.</cite> A
trip report by Cooper dated November 3, 1972 states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Volder has had excellent success in GORE-TEX
  arteries and veins. The artery work has been perfect
  using two densities of GORE-TEX: the vein work only
  when the lower of the two densities was used. Our
  letter to Dr. Volder describing the properties of the
  two tubes he has used is in the University of Utah
  file.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><cite>Id</cite>.</i>, PX 116.17766. Dr. Volder's work was published,
"A-V Shunts Created In New Ways," <i>Transactions of the</i>
<i>Amer. Soc. for Artificial Internal Organs</i>, Vol. 20, p. 38
(November 1973), in which Dr. Volder described the structure
and properties of the Gore-Tex materials, and stated: "It is
believed that by increasing the average pore size of the
material, at the moment 5-14; [microns], it will be possible to
accelerate the process of tissue infiltration and the
development of capillaries." <i></i><cite>Id. at 39</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Several other surgeons had previously tested the Gore-Tex
material as vascular grafts in dogs. In November 1972 Cooper
provided Gore-Tex tubes of various fibrous structures to Dr.
William J. Sharp <span CLASS="page_no" data-cite="2012 bl 32360 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> at the Akron City Hospital and Dr. Glenn
Kelly at the University of Colorado Medical School. This
activity is <span CLASS="page_no" data-cite="101 uspq 2d 1658" data-cite-type="ReporterOfDecisions" data-cite-pageno="1658" data-primary-citation="101 U.S.P.Q.2d 1641">[**1658]</span> summarized in <i>Cooper v. Goldfarb</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d 1321</a> (Fed. Cir. 1998) ("<i>Cooper I</i>"), the court stating
that "In the spring of 1973, the researchers participating in
the three-structure experiment began obtaining results."
<i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1324</a>. The court stated that in "a letter dated
April 2, 1973, Dr. Sharp informed Cooper that two of his grafts
had been successful." <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20F.3d%201321&amp;summary=yes#jcite">Id. at 1324</a>. Dr. Sharp described
the characteristics of fibroblastic infiltration and the nature
of the neointima

as viewed by microscope &mdash; characteristics that Dr.
Goldfarb stated were his discovery. Dr. Sharp provided his
photomicrographs to Mr. Cooper, and wrote:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  RESULTS: Group I-416-10312-3 (.31g/cc). There were a
  total of four grafts inserted into the dog's carotid
  artery. Two remained patent in the same animal for 21
  days and 2 clotted before 21 days in another animal.
  The low power microscopic views demonstrate excellent
  fibroblastic infiltration of the wall of the graft
  (Figure # 1) and a fairly thick, but well attached
  neointima (Figure # 2). There was only moderate
  reaction externally. (Figure # 3).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
PX 116.17829, <i>Bard v. Gore</i>, <cite>No. CV 03-0597-PHX-MHM</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court also reviewed Dr. Kelly's studies, at the University
of Colorado, of various Gore-Tex materials as vascular grafts
in dogs, in which Dr. Kelly identified <span CLASS="page_no" data-cite="670 f 3d 1196" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1196" data-primary-citation="670 F.3d 1171">[*1196]</span> the structures that were
most effective. The court summarized Dr. Kelly's histological
studies and microscopic investigation of tissue ingrowth
&mdash; characteristics that Dr. Goldfarb claimed as his
discovery. The Federal Circuit summarized this work:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On April 17, 1973, Dr. Kelly sent Cooper four
  histological slides of harvested grafts. Cooper
  testified that he reviewed the slides under a
  microscope on April 22, 1973, and then photographed
  the slides, measured the fibril lengths shown, and
  recorded his conclusions in his laboratory notebook.
  The first page of Cooper's notebook contains a
  photomicrograph of a harvested graft along with a
  notation indicating that the graft was submitted by
  Dr. Kelly. The page also contains a sticker with a 100
  micron scale indicated.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
The following is written above the photomicro-graph:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I want to maximize the amount and rate of tissue
  ingrowth into Gore-Tex vascular prosthetics. Two
  qualities are necessary. 1. Uniform "poker chip"
  structure and 2. a minimal "skin" at both the O.D. and
  I.D. surfaces.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Tissue has invaded Gore-Tex where the nodes are
  approx. 10-30 microns thick and with most separations
  between nodes at about 50-100 microns. Photo # 1.
  Other structures having approximately 5-10 micron node
  dimensions and spaces from about 5-30 micron do not
  appear to allow ingrowth-Photo # 2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1325</a>. This court referred to
Kelly's photomicrographs showing tissue ingrowth and
inter-nodal separation, yet Dr. Goldfarb, before the jury,
accused Cooper of stealing Goldfarb's photomicrographs showing
tissue ingrowth and internodal separation. By the time of
trial, Cooper had died, leaving Dr. Goldfarb uncontradicted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Goldfarb had told the PTO that it was "well known in 1972
and before" that for tissue ingrowth in a vascular graft, <span CLASS="page_no" data-cite="2012 bl 32360 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> the
internodal distance must be "at least the size of a fibroblast
or red blood cell," that is, "in the range of 5-6 microns," so
that the cells can infiltrate the ePTFE pores. <i>Goldfarb</i>
<i>Decl.</i>, April 26, 1984 at &para;&para; 4-6; PX 116.9772, <i>Bard</i>
<i>v. Gore</i>, <cite>No. CV 03-0597-PHX-MHM</cite>. This is the internodal
distance that all of the investigators who preceded Goldfarb
had observed to characterize the effective Gore-Tex graft
materials. Yet at the infringement trial the jury was told that
it was Goldfarb who discovered that Gore-Tex ePTFE had these
properties and performance.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Goldfarb conceded at the infringement trial that he knew
nothing about Gore-Tex or ePTFE before the Gore employees
suggested that he participate in the test program for these
materials:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. Dr. Goldfarb, do you agree that the idea of trying
  out ePTFE tubes as an artificial vascular prosthesis
  was something that was first suggested to you by two
  Gore employees, Peter Cooper and Richard Mendenhall?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Yes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. Before the Gore employees told you about trying
  ePTFE as a vascular prosthesis, you didn't know
  anything about that material, correct?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. That's correct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. And the first suggestion from Gore came in about
  February 1973 I think you said; is that right?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. That's correct.
<span CLASS="page_no" data-cite="101 uspq 2d 1659" data-cite-type="ReporterOfDecisions" data-cite-pageno="1659" data-primary-citation="101 U.S.P.Q.2d 1641">[**1659]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Trial Tr. 677:20-678:3, Nov. 8, 2007. The record contains the
following letter from Peter Cooper dated February 14, 1973,
written after this initial contact:

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Dear Dr. Goldfarb,
<span CLASS="page_no" data-cite="670 f 3d 1197" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1197" data-primary-citation="670 F.3d 1171">[*1197]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Enclosed are a variety of sizes of GORE-TEX tubes for your
animal artery prosthetic experiments. I have also enclosed a
short length of tubing with a small flange at each end and
wonder if an anastomosis technique where a similar flange if
formed on the end of the artery and butted against the GORE-TEX
prosthetic might not be a better technique than suturing the
butt ends together.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We want to do whatever we can to help you with your project.
When additional materials or further information is needed, do
not hesitate to let us know.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Very truly yours,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  /s/ Peter B. Cooper
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plant Manager
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
PX 116.13350, <i>Bard v. Gore</i>, No. <cite>CV 03-0597-P/-IX-MHM</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On April 19, 1973 Cooper sent Dr. Goldfarb additional Gore-Tex
tubes, with a letter stating that these materials "represent
the latest attempt to achieve satisfactory patency rates in
small artery prosthetics," based on the ongoing work of the
other surgeons in the project. The Federal Circuit summarized
Dr. Goldfarb's participation:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following a meeting with Cooper and Mendenhall in
  early February, Goldfarb set up an animal research
  facility at AHI. Over the next several months, Cooper
  periodically sent Goldfarb a variety of expanded PTFE
  tubes to use in his research. Using the samples
  provided by Cooper, Goldfarb conducted a series of
  experiments consisting of 21 grafts implanted in the
  left and right carotid and left and right femoral
  arteries of seven

  dogs. . . . Goldfarb began obtaining results from
  these experiments towards the end of May of 1973.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1325-26</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Goldfarb obtained results that conformed to the results
that had been achieved by the other surgeons, and then filed a
patent application on the Gore-Tex materials that he had
received from the Gore employees. He claimed, <span CLASS="page_no" data-cite="2012 bl 32360 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> for use as
vascular grafts, the materials that he had been provided by
Gore for this purpose. He claimed these materials by the
tubular shape and size and density of the materials that he had
been provided, and by the internodal structure of the materials
that he had been provided and that he, and others before him,
had observed to provide effective tissue ingrowth.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After eighteen years of interference proceedings, the PTO
granted the patent to Goldfarb, although the PTO found and the
Federal Circuit affirmed that Cooper was the first to conceive
of the invention, including the specified internodal structure,
and held that Goldfarb's work "inures to Cooper's benefit":
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Applying the <i>Genentech</i> test to these facts,
  we hold that Goldfarb's recognition that the 2-73 RF
  graft from the Lot 459-04133-9 material was suitable
  for use as a vascular implant inures to Cooper's
  benefit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Cooper v. Goldfarb</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d 1378</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">1385</a> (Fed. Cir.
2001) ("<i>Cooper II</i>"). Goldfarb had sold his rights to
International Medical Products and Research Associates
("IMPRA"), a company that had been formed by former Gore
employees, and that was sued by Gore for infringe-ment of trade
secrets. Goldfarb later recovered his patent rights, and sold
them to Bard. Goldfarb and Bard then

sued Gore for infringement. The jury found infringement by
Gore's entire line of Gore-Tex graft human prostheses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The infringement trial was fraught with errors of law,
misstatements of fact, and confessed perjury by Dan Detton, a
witness in this case to whose testimony my <span CLASS="page_no" data-cite="670 f 3d 1198" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1198" data-primary-citation="670 F.3d 1171">[*1198]</span> colleagues on this
panel give weight. Mr. Detton admitted to perjury concerning
Goldfarb's activities in testimony that Detton gave in the
trade secret litigation between Gore and IMPRA, and Detton
admitted that his false affidavits had been filed in the Patent
Office to support Dr. Goldfarb's patent application. At the
infringement trial, after Mr. Detton had been called by Gore to
testify as to various aspects of the relationship between Gore
and Dr. Goldfarb, Gore's counsel introduced Detton's affidavits
and brought out Mr. Detton's prior false testimony:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: Is this the second affidavit that you signed
  in that meeting in January of 1976?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton. Yes, it's one of the two.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: If you would turn to paragraph 15, please, of
  Exhibit 3220 [the second affidavit]. And it's stated
  there that prior to the applicant's disclosure of the
  structure defined in the above-identified application,
  affiant, that's you, was unaware of any other vascular
  structure which incorporated a thin <span CLASS="page_no" data-cite="101 uspq 2d 1660" data-cite-type="ReporterOfDecisions" data-cite-pageno="1660" data-primary-citation="101 U.S.P.Q.2d 1641">[**1660]</span> wall (in the range
  of thicknesses between 0.2 and 0.8 millimeters). Do
  you see that?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: Yes.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: Is that a factually accurate statement, Mr.
  Detton?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: No, that would be inaccurate. That's
  contradictory to the findings that we were having, and
  the results.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Bard v. Gore</i>, No. <cite>CV03-0579-PHX-MHM</cite>, Examination of D.
Detton, Trans. 1897:19-1898:6 (Nov. 27, 2007). Bard's counsel,
in turn, also addressed the falsity of Mr. Detton's prior
testimony:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: You were asked, "As far as I can tell &mdash;
  inform me if I'm correct and tell me if I'm wrong
  &mdash; the specifications for the next 64 graft
  verification experiments were set <span CLASS="page_no" data-cite="2012 bl 32360 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> forth by Dr.
  Goldfarb about mid-June of 1973; is that about
  correct?"
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Your answer, "Correct."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Is your testimony there knowingly false or truthful?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: No, that was inaccurate testimony.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: Was it knowingly false?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: Yes, it was.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: Perjury?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: Yes, it was.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Bard v. Gore</i>, No. <cite>CV03-0579-PHX-MHM</cite>, Trans. 1915:5-15
(Nov. 27, 2007).

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority complains about my reference to Mr. Detton's
admissions of perjury, stating that it is not our appellate
role to determine credibility. I am not determining Mr.
Detton's credibility: he did that for us. He admitted that he
lied in the testimony that he gave in support of the Gore
ex-employees who formed the company IMPRA to which Goldfarb
initially assigned his patent rights, and who were sued by Gore
for misappropriation of trade secrets. He admitted that he lied
in the affidavits that were filed with the patent examiner and
that achieved allowance of the Goldfarb application. This is
not an appellate assessment of credibility &mdash; there is no
credibility to assess.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority also misstates that the Matsumoto and Volder
articles were "fairly considered" as "prior art in this
appeal," for the jury was told that the patent examiner had
fully considered these articles and had granted the patent in
light thereof. It is now admitted that the Detton affidavits,
filed in the PTO to distinguish these articles, were perjured;
Detton testified that he had told Dr. Goldfarb and Goldfarb's
counsel that he wanted to withdraw the affidavits, and they
refused.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Goldfarb's counsel used the cross-examination of Detton as a
platform for misstating to the jury that "the Federal Circuit
<span CLASS="page_no" data-cite="670 f 3d 1199" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1199" data-primary-citation="670 F.3d 1171">[*1199]</span> and the patent office determined Dr. Goldfarb had come up with
this invention," for both the Federal Circuit and the Patent
Office had determined that Cooper, not Goldfarb, had conceived
the invention. Such misstatements to the jury are typified by
this exchange:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: The date up there at the top is 22-10-73. Do
  you understand that to be October 22, 1973?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Mr. Detton: I would assume.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: And this is, just so we orient ourselves,
  some four or five months after the Federal Circuit and
  the patent office determined Dr. Goldfarb had come up
  with this invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Trial Tr. 1958:17-23, Nov. 27. 2007.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Goldfarb also told the jury that the Federal
  Circuit held that the Patent Office "affirmed the
  patent" &mdash; although neither had done so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Counsel: Okay. And this is the March 2001 opinion that
  &mdash; what was the impact of this opinion? This is
  the federal &mdash; second Federal Circuit opinion,
  Dr. Goldfarb. What's the impact of this opinion?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Goldfarb: It says that judgment &mdash; that the
  decision made by the patent office affirmed the
  patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Trial Tr. 707:17-22, Nov. 8. 2007. In a travesty of flawed
proceedings, in which almost all of the witnesses were dead,
unwilling, or hostile, misstatements of law and fact
abound.<a HREF="#fn101" name="fnref_fn101">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As a matter of law, Dr. Goldfarb cannot deprive Gore of the
invention Gore possessed and that was known to Gore and
published by others before Goldfarb entered the scene. A person
who tests a material provided to him for

testing, in the test for which the material was provided,
<span CLASS="page_no" data-cite="2012 bl 32360 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> does not become the inventor of the material and the use for
which he tested it, and does not thereby become the owner of
the material with the sole right to the use he <span CLASS="page_no" data-cite="101 uspq 2d 1661" data-cite-type="ReporterOfDecisions" data-cite-pageno="1661" data-primary-citation="101 U.S.P.Q.2d 1641">[**1661]</span> was invited to
test. As stated in <i>Shatterproof Glass Corp. v. Libbey-Owens</i>
<i>Ford Co.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20f%202d%20613&amp;summary=yes#jcite">758 F.2d 613</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20f%202d%20613&amp;summary=yes#jcite">624</a> (Fed. Cir. 1985), "An inventor
`may use the services, ideas, and aid of others in the process
of perfecting his invention without losing his right to a
patent.'" (quoting <i>Hobbs v. U.S. Atomic Energy Comm'n</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3TLKF?jcsearch=451%20f%202d%20849&amp;summary=yes#jcite">451 F.2d 849</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3TLKF?jcsearch=451%20f%202d%20849&amp;summary=yes#jcite">864</a> (5th Cir. 1971)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority states that Dr. Goldfarb invented "a
homogeneously porous vascular prosthesis" with "small nodes
interconnected by extremely fine fibrils to form an open
superstructure which will allow uniform, controlled transmural
cellular ingrowth and thereby assure the establishment and
maintenance of a thin, viable neointima as well as firm
structural integration of the graft into the body." Maj. Op.
at 4. That is incorrect; the product that the panel majority
describes is the Gore-Tex product that the Gore employees
invited Dr. Goldfarb to test as a vascular prosthesis; it was
not invented, designed, created, or produced by Goldfarb. The
Gore employees provided Goldfarb with known samples having
small nodes interconnected with fibrils, of the density and
wall thickness and internodal distance of the samples that
others had previously successfully tested as graft prostheses.
They were not Goldfarb's invention.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority also misstates, or misunderstands, the
findings of the interference, and the prior Federal Circuit
rulings. This court held that Cooper had conceived the entire
invention before, not after, Goldfarb's purported reduction to
<span CLASS="page_no" data-cite="670 f 3d 1200" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1200" data-primary-citation="670 F.3d 1171">[*1200]</span> practice. This court found that Cooper had provided Goldfarb
with the material that he tested, and that by "letter to
Goldfarb accompanying the

Lot 459-04133-9 material, Cooper described the material as
represent[ing] the latest attempt to achieve satisfactory
patency rates in small artery prosthetics, indicating that he
expected the material to be suitable as a vascular graft."
<i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1381</a>. The court "h[e]ld that
Goldfarb's recognition that the 2-73 RF graft from the Lot
459-04133-9 material was suitable for use as a vascular implant
inures to Cooper's benefit." <i></i><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20F.3d%201378&amp;summary=yes#jcite">Id. at 1385</a>. The court's
inquiry into "whether Cooper can obtain the benefit of
Goldfarb's knowledge of the fibril lengths of the material
Goldfarb tested" was directed to the interference contest
between Cooper and Goldfarb, for it was undisputed that Cooper
had knowledge of the structure of the successful products
before Goldfarb tested the successful products.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus this court held in <i>Cooper I</i> that Cooper had
conceived the invention, including the fibril length
limitation, before Goldfarb reduced the invention to practice.
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1326</a>. The letter from Dr. Sharp dated April 2, 1973
related to the Lot 459-04133-9 material, and Cooper's letter to
Dr. Goldfarb on April 19, 1973 accompanied the Lot 459-04133-9
material and described it as "represent[ing] the latest attempt
to achieve satisfactory patency rates in small artery
prosthetics." <i>Cooper II</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1384</a>. This was
the material that Dr. Goldfarb <span CLASS="page_no" data-cite="2012 bl 32360 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[***27]</span> patented as his own, although
pictures of the fibrous structure of the Gore-Tex grafts had
been made known to Cooper by Dr. Sharp and Dr. Allen, and had
been published by Dr. Matsumoto and Dr. Volder.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whatever Dr. Goldfarb's contribution, he did not invent the
effective graft materials. The "microscopic superstructure of
uniformly distributed nodes interconnected by fibrils," as the
product is described by the panel majority, was the known
structure of the Gore-Tex materials that others had already
successfully tested as grafts

at Gore's request. The "uniform, controlled transmural
cellular ingrowth and thereby assure the establishment and
maintenance of a thin, viable neointima as well as firm
structural integration of the graft into the body," was
recorded in Cooper's laboratory notebook before Goldfarb was
first contacted by Cooper and Mendenhall. In <i>Cooper II</i>
the court observed that the graft identified as 2-73 RF had
been successfully tested before it was given to Goldfarb, and
that Cooper "expected the material to be suitable as a vascular
graft" and "intended that Goldfarb use the [material] for
vascular grafts, and to that extent Goldfarb's experiments
could be said to have been performed at Cooper's request."
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X50GSJ?jcsearch=240%20f%203d%201378&amp;summary=yes#jcite">240 F.3d at 1384</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the infringement trial, Gore raised the separate defense to
the infringement charge, that even if the Goldfarb patent is
not now subject to challenge, Gore's employee Cooper, who was
acknowledged to have conceived the invention, was at least a
"joint inventor" in terms of <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEJ000003?jcsearch=35%20usc%20116&amp;summary=yes#jcite">35 U.S.C. &sect; 116</a>. The panel
majority cites several cases to negate any access to joint
inventorship, although this court had already found that Cooper
conceived the invention that Goldfarb patented. Precedent
illustrates that "inventorship" and "joint invention" have been
disputed in a variety of situations, although none reached a
result that entirely excluded the person who conceived the
invention that was patented. I review the cases relied on by
the panel majority to support the exclusion of Cooper as an
inventor:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Nartron Corp. v. Schukra U.S.A., Inc.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1AM264003?jcsearch=558%20f%203d%201352&amp;summary=yes#jcite">558 F.3d 1352</a> (Fed. Cir. 2009), the question was whether an additional
employee <span CLASS="page_no" data-cite="670 f 3d 1201" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1201" data-primary-citation="670 F.3d 1171">[*1201]</span> of the patentee should have been joined as an
additional inventor; it was held that the decision of joinder
depended on <span CLASS="page_no" data-cite="101 uspq 2d 1662" data-cite-type="ReporterOfDecisions" data-cite-pageno="1662" data-primary-citation="101 U.S.P.Q.2d 1641">[**1662]</span> whether the additional employee made a significant
contribution; but the persons who conceived the invention were
not thereby excluded. In <i>Eli</i>

<i>Lilly &amp; Co. v. Aradigm Corp.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEQ9KA?jcsearch=376%20f%203d%201352&amp;summary=yes#jcite">376 F.3d 1352</a>
(Fed. Cir. 2004), the question was whether the information
discussed during various technical meetings on possible
collaboration led to joint invention; it was held that it
depended on which ideas were discussed and their relation to
the patented subject matter. In <i>University of Pittsburgh v.</i>
<i>Hedrick</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BC6D2003?jcsearch=573%20f%203d%201290&amp;summary=yes#jcite">573 F.3d 1290</a> (Fed. Cir. 2009), the question was
whether a research assistant was a joint inventor along with
the senior scientists; the court held that the assistant was
not a joint inventor because the invention had already been
conceived. The court recognized the rule that invention turns
on conception, not reduction to practice. In <i>Fina Oil</i>
<i>&amp; Chem. Co. v. Ewen</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3L8PJ?jcsearch=123%20f%203d%201466&amp;summary=yes#jcite">123 F.3d 1466</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X3L8PJ?jcsearch=123%20f%203d%201466&amp;summary=yes#jcite">1473</a> (Fed. Cir. 1997),
<span CLASS="page_no" data-cite="2012 bl 32360 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[***28]</span> the court explained that <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XEJ000003?jcsearch=35%20usc%20116&amp;summary=yes#jcite">35 U.S.C. &sect; 116</a> "sets no explicit
lower limit on the quantum or quality of inventive contribution
required for a person to qualify as a joint inventor. Rather, a
joint invention is simply the product of a collaboration
between two or more persons working together to solve the
problem addressed." In <i>Pannu v. Iolab Corp.</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X54V38?jcsearch=155%20f%203d%201344&amp;summary=yes#jcite">155 F.3d 1344</a> (Fed. Cir. 1998), the patent application was already on
file when the claimant to joint inventorship status appeared as
a possible licensee; the invention had already been conceived.
In <i>Hess v. Advanced Cardiovascular Sys.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X37H09?jcsearch=106%20f%203d%20976&amp;summary=yes#jcite">106 F.3d 976</a>
(Fed. Cir. 1997), doctors who were working on a new catheter
obtained technical advice and samples of material from a
purveyor of Raytheon tubing; the court held that this did not
convert the adviser into a joint inventor of the catheter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  None of these determinations rejecting "joint invention" tracks
the facts herein. No precedent holds, or suggests, that a
person who tests a material provided by someone else, for the
use for which the material was provided, becomes the sole
inventor of the material he was provided and the sole inventor
of the use for which he

was invited to test the material provided. The cases cited
by the panel majority support Gore's position, not Goldfarb's,
for in all cases the person who conceived the invention was an
inventor, whether or not other persons had also contributed
sufficiently to be included in inventor-ship.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the infringement trial, the jury found that Cooper and
Goldfarb were not "joint inventors," apparently because of
Goldfarb's testimony that they did not have an "open line of
communication during . . . their inventive effort," as the
district court instructed the jury. Jury Instr. #25, Doc.
769-2, p. 40-41 ("Persons may be joint or co-inventors even
though they do not physically work together, but they must have
some open line of communication during or at approximately the
time of their inventive effort."). I take note that witness Dan
Detton, whose direct supervisor was Peter Cooper, testified
that he was assigned to visit Dr. Goldfarb weekly during this
work.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury was told, over and over, that the Federal Circuit had
decided that Dr. Goldfarb was the sole inventor (although the
Federal Circuit found that Cooper, not Goldfarb, conceived the
invention); that Cooper and Goldfarb did not communicate; and
other aspects that Cooper, in death, could not contradict.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether or not there was some form of joint invention that
could include Goldfarb, Gore cannot be excluded from the right
to continue to do that which it disclosed to Goldfarb and had
previously been published by Matsumoto and Volder. Even on
Goldfarb's theory that he made useful observations, it has been
clear since <i>General Electric Co. v. Jewel Incandescent Lamp</i>
<i>Co.<span CLASS="page_no" data-cite="670 f 3d 1202" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1202" data-primary-citation="670 F.3d 1171">[*1202]</span> </i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C0UB?jcsearch=326%20us%20242&amp;summary=yes#jcite">326 U.S. 242</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C0UB?jcsearch=326%20us%20242&amp;summary=yes#jcite">249</a> (1945), that "It is not invention
to perceive that the product which others had discovered had
qualities they failed to detect." <i>See In re Kubin</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">561 F.3d 1351</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">1357</a>

(Fed. Cir. 2009) (the discovery of an inherent property of
a known composition does not render the composition patentable
to the observer of the inherent property).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The PTO found and the Federal Circuit <span CLASS="page_no" data-cite="2012 bl 32360 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[***29]</span> affirmed that Cooper was
the first to conceive the invention, and that Cooper provided
Goldfarb with the material embodying the invention for further
testing by Goldfarb, <i>see Cooper I</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X369UL?jcsearch=154%20f%203d%201321&amp;summary=yes#jcite">154 F.3d at 1330</a>.
These rulings have never been challenged, even in the conceded
perjured testimony, and totally negate the panel majority's
claims on behalf of Goldfarb. The law has heretofore been clear
that a person who tests a product provided by another, for the
purpose designated by the provider, cannot acquire the
exclusive right to that product for that use, to the exclusion
of the inventor of the use. Such a rule violates the most
fundamental premises of patent law and property rights. The
panel majority's endorsement of such a rule will breed much
mischief, to the disruption of routine testing relationships.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My colleagues, applying these flawed rulings, affirm that Gore
willfully infringed the Goldfarb patent on the product that
Gore invented, developed, and commercialized. My colleagues
hold that Bard, who purchased Goldfarb's rights, is entitled to
all of Gore's profits on all Gore-Tex graft materials. Yet the
entire history is permeated by errors of fact <span CLASS="page_no" data-cite="101 uspq 2d 1663" data-cite-type="ReporterOfDecisions" data-cite-pageno="1663" data-primary-citation="101 U.S.P.Q.2d 1641">[**1663]</span> and law, lies,
inconsistencies, and injustice. In <i>Shatterproof Glass</i>,
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/XABQ82?jcsearch=758%20F.2d%20at%20626&amp;summary=yes#jcite">758 F.2d at 626</a>, this court stated that "If prejudicial error
occurred, or if the verdict is against the clear weight of the
evidence, as an alternative to judgment n.o.v. a new trial may
be granted, in the discretion of the trial judge." It is
apparent that "the verdict is against the weight of the
evidence, that the damages are excessive, or that, for other
reasons, the trial was not fair to the party moving."
<i>Montgomery Ward &amp; Co. v. Duncan</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C052?jcsearch=311%20us%20243&amp;summary=yes#jcite">311 U.S. 243</a>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5C052?jcsearch=311%20us%20243&amp;summary=yes#jcite">251</a>
(1940). <i>See Fairmont</i>

<i>Glass Works v. Cub Fork Coal Co.</i>, <a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X5BUKV?jcsearch=287%20us%20474&amp;summary=yes#jcite">287 U.S. 474</a>
(1933) (a new trial should be granted when justice requires).
At a minimum a new trial is required, lest we "make a
scare-crow of the law."<a HREF="#fn201" name="fnref_fn201">[fn2]</a> From the panel majority's
ratification of this insult to judicial process, I respectfully
dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> I take note of the panel majority's observation that this
saga has overtones of a Shakespearian tragedy, for these events
indeed illustrate that "to be honest, as this world goes, is to
be one man picked out of ten thousand." W. Shakespeare,
<i>Hamlet</i>, Act II, sc. ii.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> We must not make a scarecrow of the law, Setting it up to
fear the birds of prey, And let it keep one shape, till custom
make it Their perch and not their terror. W. Shakespeare,
<i>Measure for Measure</i>, Act II, sc. ii.

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<!--BBLS DD 1688765136899-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H4P3U003/history">Direct History (21)</a>
</div>
<div class='sidebarItemLabel bold'>
Negative Direct History
</div>
<div class='bcite'>
<div class='sidebarItemLabel'>
Opinion affirmed (in part) and opinion vacated (in part) by
</div>
<div class='citationAnalysisSideBarLabel'>
<a class="icon citation positive" href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BM6B8N" title="Positive"></a>
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1BM6B8N">Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 682 F.3d 1003, 103 U.S.P.Q.2d 1088 (Fed. Cir. 2012)</a>
</div>
</div>

<div class='bcite'>
<div class='sidebarItemLabel'>
Judgment vacated (in part) and rehearing granted and appeal denied and opinion modified (Per curiam) by
</div>
<div class='citationAnalysisSideBarLabel'>
<a class="icon citation positive" href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1EIDD8N" title="Positive"></a>
<a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1EIDD8N">Bard Peripheral Vascular, Inc. v. W.L. Gore &amp; Assocs., 476 Fed. Appx. 747 (Fed. Cir. 2012)</a>
</div>
</div>

</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H4P3U003/analysis">Case Analysis (15)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H4P3U003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
15
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Devices</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/document/X1Q6LDS3BKO2">10-01510 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/a4610bb61aea3199fe1b6cfffdb7f388/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "a4610bb61aea3199fe1b6cfffdb7f388";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYeff58e&previousPageId=&previousActivityInstanceId=ENTITY1aa4ce&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:35:15-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1H4P3U003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY1aa4ce&previousPageId=&previousActivityInstanceId=ENTITY5e6a45&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:35:06-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1H4P3U003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1H4P3U003";
$('#page_loader').show().spin();
JUDGE_IDS=["1850676","1910097","3496219"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
